{
  "Visitid": "ABCDEFG1234",
  "Diagnosisid": "86de5775-e7f3-49be-90bd-92af8017ad23",
  "RupleResults": [
    "{\"DisplayName\":\"thrombocytopenia\",\"chartData\":[[{\"y\":[\"95\",\"130\",\"76\",\"79\",\"93\",\"91\",\"80\",\"84\",\"87\",\"94\",\"87\",\"96\",\"99\",\"98\",\"84\",\"97\",\"84\",\"81\",\"90\",\"87\",\"87\",\"86\",\"92\",\"97\",\"118\",\"134\",\"116\",\"134\",\"112\",\"139\"],\"x\":[\"2021-06-21T04:00:00.000Z\",\"2021-06-21T04:00:00.000Z\",\"2021-06-22T04:00:00.000Z\",\"2021-06-22T04:00:00.000Z\",\"2021-06-23T04:00:00.000Z\",\"2021-06-23T04:00:00.000Z\",\"2021-06-23T04:00:00.000Z\",\"2021-06-24T04:00:00.000Z\",\"2021-06-24T04:00:00.000Z\",\"2021-06-25T04:00:00.000Z\",\"2021-06-26T04:00:00.000Z\",\"2021-06-26T04:00:00.000Z\",\"2021-06-27T04:00:00.000Z\",\"2021-06-27T04:00:00.000Z\",\"2021-06-28T04:00:00.000Z\",\"2021-06-28T04:00:00.000Z\",\"2021-06-29T04:00:00.000Z\",\"2021-06-30T04:00:00.000Z\",\"2021-07-01T04:00:00.000Z\",\"2021-07-02T04:00:00.000Z\",\"2021-07-02T04:00:00.000Z\",\"2021-07-03T04:00:00.000Z\",\"2021-07-04T04:00:00.000Z\",\"2021-07-04T04:00:00.000Z\",\"2021-07-05T04:00:00.000Z\",\"2021-07-06T04:00:00.000Z\",\"2021-07-06T04:00:00.000Z\",\"2021-07-07T04:00:00.000Z\",\"2021-07-08T04:00:00.000Z\",\"2021-07-08T04:00:00.000Z\"],\"type\":\"scatter\",\"mode\":\"lines+markers\",\"name\":\"Platelet count\",\"marker\":{\"size\":4,\"color\":\"#CE944F\"}},{\"y\":[\"95\",\"95\",\"76\",\"76\",\"93\",\"93\",\"93\",\"84\",\"84\",\"94\",\"87\",\"87\",\"99\",\"99\",\"84\",\"84\",\"84\",\"81\",\"90\",\"87\",\"87\",\"86\",\"92\",\"92\",\"118\",\"134\",\"134\",\"134\",\"112\",\"112\"],\"x\":[\"2021-06-21T04:00:00.000Z\",\"2021-06-21T04:00:00.000Z\",\"2021-06-22T04:00:00.000Z\",\"2021-06-22T04:00:00.000Z\",\"2021-06-23T04:00:00.000Z\",\"2021-06-23T04:00:00.000Z\",\"2021-06-23T04:00:00.000Z\",\"2021-06-24T04:00:00.000Z\",\"2021-06-24T04:00:00.000Z\",\"2021-06-25T04:00:00.000Z\",\"2021-06-26T04:00:00.000Z\",\"2021-06-26T04:00:00.000Z\",\"2021-06-27T04:00:00.000Z\",\"2021-06-27T04:00:00.000Z\",\"2021-06-28T04:00:00.000Z\",\"2021-06-28T04:00:00.000Z\",\"2021-06-29T04:00:00.000Z\",\"2021-06-30T04:00:00.000Z\",\"2021-07-01T04:00:00.000Z\",\"2021-07-02T04:00:00.000Z\",\"2021-07-02T04:00:00.000Z\",\"2021-07-03T04:00:00.000Z\",\"2021-07-04T04:00:00.000Z\",\"2021-07-04T04:00:00.000Z\",\"2021-07-05T04:00:00.000Z\",\"2021-07-06T04:00:00.000Z\",\"2021-07-06T04:00:00.000Z\",\"2021-07-07T04:00:00.000Z\",\"2021-07-08T04:00:00.000Z\",\"2021-07-08T04:00:00.000Z\"],\"type\":\"scatter\",\"mode\":\"markers\",\"marker\":{\"size\":4,\"color\":\"black\"},\"showlegend\":false}],[{\"y\":[\"95\",\"130\",\"76\",\"79\",\"93\",\"91\",\"80\",\"84\",\"87\",\"94\",\"87\",\"96\",\"99\",\"98\",\"84\",\"97\",\"84\",\"81\",\"90\",\"87\",\"87\",\"86\",\"92\",\"97\",\"118\",\"134\",\"116\",\"134\",\"112\",\"139\"],\"x\":[\"2021-06-21T04:00:00.000Z\",\"2021-06-21T04:00:00.000Z\",\"2021-06-22T04:00:00.000Z\",\"2021-06-22T04:00:00.000Z\",\"2021-06-23T04:00:00.000Z\",\"2021-06-23T04:00:00.000Z\",\"2021-06-23T04:00:00.000Z\",\"2021-06-24T04:00:00.000Z\",\"2021-06-24T04:00:00.000Z\",\"2021-06-25T04:00:00.000Z\",\"2021-06-26T04:00:00.000Z\",\"2021-06-26T04:00:00.000Z\",\"2021-06-27T04:00:00.000Z\",\"2021-06-27T04:00:00.000Z\",\"2021-06-28T04:00:00.000Z\",\"2021-06-28T04:00:00.000Z\",\"2021-06-29T04:00:00.000Z\",\"2021-06-30T04:00:00.000Z\",\"2021-07-01T04:00:00.000Z\",\"2021-07-02T04:00:00.000Z\",\"2021-07-02T04:00:00.000Z\",\"2021-07-03T04:00:00.000Z\",\"2021-07-04T04:00:00.000Z\",\"2021-07-04T04:00:00.000Z\",\"2021-07-05T04:00:00.000Z\",\"2021-07-06T04:00:00.000Z\",\"2021-07-06T04:00:00.000Z\",\"2021-07-07T04:00:00.000Z\",\"2021-07-08T04:00:00.000Z\",\"2021-07-08T04:00:00.000Z\"],\"type\":\"scatter\",\"mode\":\"lines+markers\",\"name\":\" Platelet count\",\"marker\":{\"size\":4,\"color\":\"#CE944F\"}},{\"y\":[\"95\",\"95\",\"76\",\"76\",\"93\",\"93\",\"93\",\"84\",\"84\",\"94\",\"87\",\"87\",\"99\",\"99\",\"84\",\"84\",\"84\",\"81\",\"90\",\"87\",\"87\",\"86\",\"92\",\"92\",\"118\",\"134\",\"134\",\"134\",\"112\",\"112\"],\"x\":[\"2021-06-21T04:00:00.000Z\",\"2021-06-21T04:00:00.000Z\",\"2021-06-22T04:00:00.000Z\",\"2021-06-22T04:00:00.000Z\",\"2021-06-23T04:00:00.000Z\",\"2021-06-23T04:00:00.000Z\",\"2021-06-23T04:00:00.000Z\",\"2021-06-24T04:00:00.000Z\",\"2021-06-24T04:00:00.000Z\",\"2021-06-25T04:00:00.000Z\",\"2021-06-26T04:00:00.000Z\",\"2021-06-26T04:00:00.000Z\",\"2021-06-27T04:00:00.000Z\",\"2021-06-27T04:00:00.000Z\",\"2021-06-28T04:00:00.000Z\",\"2021-06-28T04:00:00.000Z\",\"2021-06-29T04:00:00.000Z\",\"2021-06-30T04:00:00.000Z\",\"2021-07-01T04:00:00.000Z\",\"2021-07-02T04:00:00.000Z\",\"2021-07-02T04:00:00.000Z\",\"2021-07-03T04:00:00.000Z\",\"2021-07-04T04:00:00.000Z\",\"2021-07-04T04:00:00.000Z\",\"2021-07-05T04:00:00.000Z\",\"2021-07-06T04:00:00.000Z\",\"2021-07-06T04:00:00.000Z\",\"2021-07-07T04:00:00.000Z\",\"2021-07-08T04:00:00.000Z\",\"2021-07-08T04:00:00.000Z\"],\"type\":\"scatter\",\"mode\":\"markers\",\"marker\":{\"size\":4,\"color\":\"black\"},\"showlegend\":false},{\"y\":[\"76\"],\"x\":[\"2021-06-22T04:00:00.000Z\"],\"type\":\"scatter\",\"mode\":\"markers\",\"marker\":{\"size\":8,\"color\":\"black\"},\"showlegend\":false}],[{\"y\":[\"\"],\"x\":[\"2021-06-30T04:00:00.000Z\"],\"type\":\"scatter\",\"mode\":\"lines+markers\",\"name\":\"SCDs noted\",\"marker\":{\"size\":4,\"color\":\"#CE944F\"}},{\"y\":[\"\"],\"x\":[\"2021-06-30T04:00:00.000Z\"],\"type\":\"scatter\",\"mode\":\"markers\",\"marker\":{\"size\":4,\"color\":\"black\"},\"showlegend\":false}],[{\"y\":[\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\"],\"x\":[\"2021-06-24T04:00:00.000Z\",\"2021-06-25T04:00:00.000Z\",\"2021-06-26T04:00:00.000Z\",\"2021-06-27T04:00:00.000Z\",\"2021-06-28T04:00:00.000Z\",\"2021-06-29T04:00:00.000Z\",\"2021-06-30T04:00:00.000Z\",\"2021-06-30T04:00:00.000Z\",\"2021-07-01T04:00:00.000Z\"],\"type\":\"scatter\",\"mode\":\"lines+markers\",\"name\":\"SCDs noted\",\"marker\":{\"size\":4,\"color\":\"#CE944F\"}},{\"y\":[\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\"],\"x\":[\"2021-06-24T04:00:00.000Z\",\"2021-06-25T04:00:00.000Z\",\"2021-06-26T04:00:00.000Z\",\"2021-06-27T04:00:00.000Z\",\"2021-06-28T04:00:00.000Z\",\"2021-06-29T04:00:00.000Z\",\"2021-06-30T04:00:00.000Z\",\"2021-06-30T04:00:00.000Z\",\"2021-07-01T04:00:00.000Z\"],\"type\":\"scatter\",\"mode\":\"markers\",\"marker\":{\"size\":4,\"color\":\"black\"},\"showlegend\":false}],[{\"y\":[\"\",\"\",\"\",\"\"],\"x\":[\"2021-06-26T04:00:00.000Z\",\"2021-06-29T04:00:00.000Z\",\"2021-07-04T04:00:00.000Z\",\"2021-07-05T04:00:00.000Z\"],\"type\":\"scatter\",\"mode\":\"lines+markers\",\"name\":\"Thrombocytopenia noted\",\"marker\":{\"size\":4,\"color\":\"#CE944F\"}},{\"y\":[\"\",\"\",\"\",\"\"],\"x\":[\"2021-06-26T04:00:00.000Z\",\"2021-06-29T04:00:00.000Z\",\"2021-07-04T04:00:00.000Z\",\"2021-07-05T04:00:00.000Z\"],\"type\":\"scatter\",\"mode\":\"markers\",\"marker\":{\"size\":4,\"color\":\"black\"},\"showlegend\":false}],[{\"y\":[\"7\"],\"x\":[\"2021-07-08T04:00:00.000Z\"],\"type\":\"scatter\",\"mode\":\"lines+markers\",\"name\":\"diagnosis_pancytopenia_present\",\"marker\":{\"size\":4,\"color\":\"#CE944F\"}},{\"y\":[\"7\"],\"x\":[\"2021-07-08T04:00:00.000Z\"],\"type\":\"scatter\",\"mode\":\"markers\",\"marker\":{\"size\":4,\"color\":\"black\"},\"showlegend\":false}],[{\"y\":[\"\"],\"x\":[\"2021-06-24T04:00:00.000Z\"],\"type\":\"scatter\",\"mode\":\"lines+markers\",\"name\":\"AC held\",\"marker\":{\"size\":4,\"color\":\"#CE944F\"}},{\"y\":[\"\"],\"x\":[\"2021-06-24T04:00:00.000Z\"],\"type\":\"scatter\",\"mode\":\"markers\",\"marker\":{\"size\":4,\"color\":\"black\"},\"showlegend\":false}],[{\"y\":[\"\",\"\"],\"x\":[\"2021-06-30T04:00:00.000Z\",\"2021-07-08T04:00:00.000Z\"],\"type\":\"scatter\",\"mode\":\"lines+markers\",\"name\":\"AC held\",\"marker\":{\"size\":4,\"color\":\"#CE944F\"}},{\"y\":[\"\",\"\"],\"x\":[\"2021-06-30T04:00:00.000Z\",\"2021-07-08T04:00:00.000Z\"],\"type\":\"scatter\",\"mode\":\"markers\",\"marker\":{\"size\":4,\"color\":\"black\"},\"showlegend\":false}],[{\"y\":[\"\",\"\",\"\"],\"x\":[\"2021-06-28T04:00:00.000Z\",\"2021-06-30T04:00:00.000Z\",\"2021-07-03T04:00:00.000Z\"],\"type\":\"scatter\",\"mode\":\"lines+markers\",\"name\":\"Bleeding noted\",\"marker\":{\"size\":4,\"color\":\"#CE944F\"}},{\"y\":[\"\",\"\",\"\"],\"x\":[\"2021-06-28T04:00:00.000Z\",\"2021-06-30T04:00:00.000Z\",\"2021-07-03T04:00:00.000Z\"],\"type\":\"scatter\",\"mode\":\"markers\",\"marker\":{\"size\":4,\"color\":\"black\"},\"showlegend\":false}],[{\"y\":[\"\"],\"x\":[\"2021-06-23T04:00:00.000Z\"],\"type\":\"scatter\",\"mode\":\"lines+markers\",\"name\":\"GIB noted\",\"marker\":{\"size\":4,\"color\":\"#CE944F\"}},{\"y\":[\"\"],\"x\":[\"2021-06-23T04:00:00.000Z\"],\"type\":\"scatter\",\"mode\":\"markers\",\"marker\":{\"size\":4,\"color\":\"black\"},\"showlegend\":false}],[{\"y\":[\"\",\"\",\"\",\"\"],\"x\":[\"2021-06-26T04:00:00.000Z\",\"2021-06-29T04:00:00.000Z\",\"2021-07-04T04:00:00.000Z\",\"2021-07-05T04:00:00.000Z\"],\"type\":\"scatter\",\"mode\":\"lines+markers\",\"name\":\"Thrombocytopenia noted\",\"marker\":{\"size\":4,\"color\":\"#CE944F\"}},{\"y\":[\"\",\"\",\"\",\"\"],\"x\":[\"2021-06-26T04:00:00.000Z\",\"2021-06-29T04:00:00.000Z\",\"2021-07-04T04:00:00.000Z\",\"2021-07-05T04:00:00.000Z\"],\"type\":\"scatter\",\"mode\":\"markers\",\"marker\":{\"size\":4,\"color\":\"black\"},\"showlegend\":false}]],\"triggerData\":[{\"type\":\"single\",\"hide\":false,\"triggeredAt\":[],\"details\":[[{\"type\":\"labs\",\"name\":\"plt\",\"visitid\":\"ABCDEFG1234\",\"value\":\"95\",\"date\":\"2021-06-21\",\"timestamp\":\"2021-06-21 00:00:00\",\"value_text_sentences\":[\"95.0\"],\"orderTimestamp\":1443196800000},{\"type\":\"labs\",\"name\":\"plt\",\"visitid\":\"ABCDEFG1234\",\"value\":\"130\",\"date\":\"2021-06-21\",\"timestamp\":\"2021-06-21 00:00:00\",\"value_text_sentences\":[\"130.0\"],\"orderTimestamp\":1443196800000},{\"type\":\"labs\",\"name\":\"plt\",\"visitid\":\"ABCDEFG1234\",\"value\":\"76\",\"date\":\"2021-06-22\",\"timestamp\":\"2021-06-22 00:00:00\",\"value_text_sentences\":[\"76.0\"],\"orderTimestamp\":1443283200000},{\"type\":\"labs\",\"name\":\"plt\",\"visitid\":\"ABCDEFG1234\",\"value\":\"79\",\"date\":\"2021-06-22\",\"timestamp\":\"2021-06-22 00:00:00\",\"value_text_sentences\":[\"79.0\"],\"orderTimestamp\":1443283200000},{\"type\":\"labs\",\"name\":\"plt\",\"visitid\":\"ABCDEFG1234\",\"value\":\"80\",\"date\":\"2021-06-23\",\"timestamp\":\"2021-06-23 00:00:00\",\"value_text_sentences\":[\"80.0\"],\"orderTimestamp\":1443369600000},{\"type\":\"labs\",\"name\":\"plt\",\"visitid\":\"ABCDEFG1234\",\"value\":\"93\",\"date\":\"2021-06-23\",\"timestamp\":\"2021-06-23 00:00:00\",\"value_text_sentences\":[\"93.0\"],\"orderTimestamp\":1443369600000},{\"type\":\"labs\",\"name\":\"plt\",\"visitid\":\"ABCDEFG1234\",\"value\":\"91\",\"date\":\"2021-06-23\",\"timestamp\":\"2021-06-23 00:00:00\",\"value_text_sentences\":[\"91.0\"],\"orderTimestamp\":1443369600000},{\"type\":\"labs\",\"name\":\"plt\",\"visitid\":\"ABCDEFG1234\",\"value\":\"84\",\"date\":\"2021-06-24\",\"timestamp\":\"2021-06-24 00:00:00\",\"value_text_sentences\":[\"84.0\"],\"orderTimestamp\":1443456000000},{\"type\":\"labs\",\"name\":\"plt\",\"visitid\":\"ABCDEFG1234\",\"value\":\"87\",\"date\":\"2021-06-24\",\"timestamp\":\"2021-06-24 00:00:00\",\"value_text_sentences\":[\"87.0\"],\"orderTimestamp\":1443456000000},{\"type\":\"labs\",\"name\":\"plt\",\"visitid\":\"ABCDEFG1234\",\"value\":\"94\",\"date\":\"2021-06-25\",\"timestamp\":\"2021-06-25 00:00:00\",\"value_text_sentences\":[\"94.0\"],\"orderTimestamp\":1443542400000},{\"type\":\"labs\",\"name\":\"plt\",\"visitid\":\"ABCDEFG1234\",\"value\":\"87\",\"date\":\"2021-06-26\",\"timestamp\":\"2021-06-26 00:00:00\",\"value_text_sentences\":[\"87.0\"],\"orderTimestamp\":1443628800000},{\"type\":\"labs\",\"name\":\"plt\",\"visitid\":\"ABCDEFG1234\",\"value\":\"96\",\"date\":\"2021-06-26\",\"timestamp\":\"2021-06-26 00:00:00\",\"value_text_sentences\":[\"96.0\"],\"orderTimestamp\":1443628800000},{\"type\":\"labs\",\"name\":\"plt\",\"visitid\":\"ABCDEFG1234\",\"value\":\"99\",\"date\":\"2021-06-27\",\"timestamp\":\"2021-06-27 00:00:00\",\"value_text_sentences\":[\"99.0\"],\"orderTimestamp\":1443715200000},{\"type\":\"labs\",\"name\":\"plt\",\"visitid\":\"ABCDEFG1234\",\"value\":\"98\",\"date\":\"2021-06-27\",\"timestamp\":\"2021-06-27 00:00:00\",\"value_text_sentences\":[\"98.0\"],\"orderTimestamp\":1443715200000},{\"type\":\"labs\",\"name\":\"plt\",\"visitid\":\"ABCDEFG1234\",\"value\":\"84\",\"date\":\"2021-06-28\",\"timestamp\":\"2021-06-28 00:00:00\",\"value_text_sentences\":[\"84.0\"],\"orderTimestamp\":1443801600000},{\"type\":\"labs\",\"name\":\"plt\",\"visitid\":\"ABCDEFG1234\",\"value\":\"97\",\"date\":\"2021-06-28\",\"timestamp\":\"2021-06-28 00:00:00\",\"value_text_sentences\":[\"97.0\"],\"orderTimestamp\":1443801600000},{\"type\":\"labs\",\"name\":\"plt\",\"visitid\":\"ABCDEFG1234\",\"value\":\"84\",\"date\":\"2021-06-29\",\"timestamp\":\"2021-06-29 00:00:00\",\"value_text_sentences\":[\"84.0\"],\"orderTimestamp\":1443888000000},{\"type\":\"labs\",\"name\":\"plt\",\"visitid\":\"ABCDEFG1234\",\"value\":\"81\",\"date\":\"2021-06-30\",\"timestamp\":\"2021-06-30 00:00:00\",\"value_text_sentences\":[\"81.0\"],\"orderTimestamp\":1443974400000},{\"type\":\"labs\",\"name\":\"plt\",\"visitid\":\"ABCDEFG1234\",\"value\":\"90\",\"date\":\"2021-07-01\",\"timestamp\":\"2021-07-01 00:00:00\",\"value_text_sentences\":[\"90.0\"],\"orderTimestamp\":1444060800000},{\"type\":\"labs\",\"name\":\"plt\",\"visitid\":\"ABCDEFG1234\",\"value\":\"87\",\"date\":\"2021-07-02\",\"timestamp\":\"2021-07-02 00:00:00\",\"value_text_sentences\":[\"87.0\"],\"orderTimestamp\":1444147200000},{\"type\":\"labs\",\"name\":\"plt\",\"visitid\":\"ABCDEFG1234\",\"value\":\"87\",\"date\":\"2021-07-02\",\"timestamp\":\"2021-07-02 00:00:00\",\"value_text_sentences\":[\"87.0\"],\"orderTimestamp\":1444147200000},{\"type\":\"labs\",\"name\":\"plt\",\"visitid\":\"ABCDEFG1234\",\"value\":\"86\",\"date\":\"2021-07-03\",\"timestamp\":\"2021-07-03 00:00:00\",\"value_text_sentences\":[\"86.0\"],\"orderTimestamp\":1444233600000},{\"type\":\"labs\",\"name\":\"plt\",\"visitid\":\"ABCDEFG1234\",\"value\":\"92\",\"date\":\"2021-07-04\",\"timestamp\":\"2021-07-04 00:00:00\",\"value_text_sentences\":[\"92.0\"],\"orderTimestamp\":1444320000000},{\"type\":\"labs\",\"name\":\"plt\",\"visitid\":\"ABCDEFG1234\",\"value\":\"97\",\"date\":\"2021-07-04\",\"timestamp\":\"2021-07-04 00:00:00\",\"value_text_sentences\":[\"97.0\"],\"orderTimestamp\":1444320000000},{\"type\":\"labs\",\"name\":\"plt\",\"visitid\":\"ABCDEFG1234\",\"value\":\"118\",\"date\":\"2021-07-05\",\"timestamp\":\"2021-07-05 00:00:00\",\"value_text_sentences\":[\"118.0\"],\"orderTimestamp\":1444406400000},{\"type\":\"labs\",\"name\":\"plt\",\"visitid\":\"ABCDEFG1234\",\"value\":\"116\",\"date\":\"2021-07-06\",\"timestamp\":\"2021-07-06 00:00:00\",\"value_text_sentences\":[\"116.0\"],\"orderTimestamp\":1444492800000},{\"type\":\"labs\",\"name\":\"plt\",\"visitid\":\"ABCDEFG1234\",\"value\":\"134\",\"date\":\"2021-07-06\",\"timestamp\":\"2021-07-06 00:00:00\",\"value_text_sentences\":[\"134.0\"],\"orderTimestamp\":1444492800000},{\"type\":\"labs\",\"name\":\"plt\",\"visitid\":\"ABCDEFG1234\",\"value\":\"134\",\"date\":\"2021-07-07\",\"timestamp\":\"2021-07-07 00:00:00\",\"value_text_sentences\":[\"134.0\"],\"orderTimestamp\":1444579200000},{\"type\":\"labs\",\"name\":\"plt\",\"visitid\":\"ABCDEFG1234\",\"value\":\"112\",\"date\":\"2021-07-08\",\"timestamp\":\"2021-07-08 00:00:00\",\"value_text_sentences\":[\"112.0\"],\"orderTimestamp\":1444665600000},{\"type\":\"labs\",\"name\":\"plt\",\"visitid\":\"ABCDEFG1234\",\"value\":\"139\",\"date\":\"2021-07-08\",\"timestamp\":\"2021-07-08 00:00:00\",\"value_text_sentences\":[\"139.0\"],\"orderTimestamp\":1444665600000}]]},{\"type\":\"timeframe\",\"hide\":false,\"triggeredAt\":1443283200000,\"combinedTimeline\":[[1632196800000,0],[1632196800000,0],[1632283200000,0],[1632283200000,0],[1632369600000,0],[1632369600000,0],[1632369600000,0],[1632456000000,0],[1632456000000,0],[1632542400000,0],[1632628800000,0],[1632628800000,0],[1632715200000,0],[1632715200000,0],[1632801600000,0],[1632801600000,0],[1632888000000,0],[1632974400000,0],[1633060800000,0],[1633147200000,0],[1633147200000,0],[1633233600000,0],[1633320000000,0],[1633320000000,0],[1633406400000,0],[1633492800000,0],[1633492800000,0],[1633579200000,0],[1633665600000,0],[1633665600000,0]],\"responsibleTriggers\":[[1632283200000,1632196800000]],\"details\":[[{\"type\":\"labs\",\"name\":\"plt\",\"visitid\":\"ABCDEFG1234\",\"value\":\"95\",\"date\":\"2021-06-21\",\"timestamp\":\"2021-06-21 00:00:00\",\"value_text_sentences\":[\"95.0\"],\"orderTimestamp\":1443196800000},{\"type\":\"labs\",\"name\":\"plt\",\"visitid\":\"ABCDEFG1234\",\"value\":\"130\",\"date\":\"2021-06-21\",\"timestamp\":\"2021-06-21 00:00:00\",\"value_text_sentences\":[\"130.0\"],\"orderTimestamp\":1443196800000},{\"type\":\"labs\",\"name\":\"plt\",\"visitid\":\"ABCDEFG1234\",\"value\":\"76\",\"date\":\"2021-06-22\",\"timestamp\":\"2021-06-22 00:00:00\",\"value_text_sentences\":[\"76.0\"],\"orderTimestamp\":1443283200000},{\"type\":\"labs\",\"name\":\"plt\",\"visitid\":\"ABCDEFG1234\",\"value\":\"79\",\"date\":\"2021-06-22\",\"timestamp\":\"2021-06-22 00:00:00\",\"value_text_sentences\":[\"79.0\"],\"orderTimestamp\":1443283200000},{\"type\":\"labs\",\"name\":\"plt\",\"visitid\":\"ABCDEFG1234\",\"value\":\"80\",\"date\":\"2021-06-23\",\"timestamp\":\"2021-06-23 00:00:00\",\"value_text_sentences\":[\"80.0\"],\"orderTimestamp\":1443369600000},{\"type\":\"labs\",\"name\":\"plt\",\"visitid\":\"ABCDEFG1234\",\"value\":\"93\",\"date\":\"2021-06-23\",\"timestamp\":\"2021-06-23 00:00:00\",\"value_text_sentences\":[\"93.0\"],\"orderTimestamp\":1443369600000},{\"type\":\"labs\",\"name\":\"plt\",\"visitid\":\"ABCDEFG1234\",\"value\":\"91\",\"date\":\"2021-06-23\",\"timestamp\":\"2021-06-23 00:00:00\",\"value_text_sentences\":[\"91.0\"],\"orderTimestamp\":1443369600000},{\"type\":\"labs\",\"name\":\"plt\",\"visitid\":\"ABCDEFG1234\",\"value\":\"84\",\"date\":\"2021-06-24\",\"timestamp\":\"2021-06-24 00:00:00\",\"value_text_sentences\":[\"84.0\"],\"orderTimestamp\":1443456000000},{\"type\":\"labs\",\"name\":\"plt\",\"visitid\":\"ABCDEFG1234\",\"value\":\"87\",\"date\":\"2021-06-24\",\"timestamp\":\"2021-06-24 00:00:00\",\"value_text_sentences\":[\"87.0\"],\"orderTimestamp\":1443456000000},{\"type\":\"labs\",\"name\":\"plt\",\"visitid\":\"ABCDEFG1234\",\"value\":\"94\",\"date\":\"2021-06-25\",\"timestamp\":\"2021-06-25 00:00:00\",\"value_text_sentences\":[\"94.0\"],\"orderTimestamp\":1443542400000},{\"type\":\"labs\",\"name\":\"plt\",\"visitid\":\"ABCDEFG1234\",\"value\":\"87\",\"date\":\"2021-06-26\",\"timestamp\":\"2021-06-26 00:00:00\",\"value_text_sentences\":[\"87.0\"],\"orderTimestamp\":1443628800000},{\"type\":\"labs\",\"name\":\"plt\",\"visitid\":\"ABCDEFG1234\",\"value\":\"96\",\"date\":\"2021-06-26\",\"timestamp\":\"2021-06-26 00:00:00\",\"value_text_sentences\":[\"96.0\"],\"orderTimestamp\":1443628800000},{\"type\":\"labs\",\"name\":\"plt\",\"visitid\":\"ABCDEFG1234\",\"value\":\"99\",\"date\":\"2021-06-27\",\"timestamp\":\"2021-06-27 00:00:00\",\"value_text_sentences\":[\"99.0\"],\"orderTimestamp\":1443715200000},{\"type\":\"labs\",\"name\":\"plt\",\"visitid\":\"ABCDEFG1234\",\"value\":\"98\",\"date\":\"2021-06-27\",\"timestamp\":\"2021-06-27 00:00:00\",\"value_text_sentences\":[\"98.0\"],\"orderTimestamp\":1443715200000},{\"type\":\"labs\",\"name\":\"plt\",\"visitid\":\"ABCDEFG1234\",\"value\":\"84\",\"date\":\"2021-06-28\",\"timestamp\":\"2021-06-28 00:00:00\",\"value_text_sentences\":[\"84.0\"],\"orderTimestamp\":1443801600000},{\"type\":\"labs\",\"name\":\"plt\",\"visitid\":\"ABCDEFG1234\",\"value\":\"97\",\"date\":\"2021-06-28\",\"timestamp\":\"2021-06-28 00:00:00\",\"value_text_sentences\":[\"97.0\"],\"orderTimestamp\":1443801600000},{\"type\":\"labs\",\"name\":\"plt\",\"visitid\":\"ABCDEFG1234\",\"value\":\"84\",\"date\":\"2021-06-29\",\"timestamp\":\"2021-06-29 00:00:00\",\"value_text_sentences\":[\"84.0\"],\"orderTimestamp\":1443888000000},{\"type\":\"labs\",\"name\":\"plt\",\"visitid\":\"ABCDEFG1234\",\"value\":\"81\",\"date\":\"2021-06-30\",\"timestamp\":\"2021-06-30 00:00:00\",\"value_text_sentences\":[\"81.0\"],\"orderTimestamp\":1443974400000},{\"type\":\"labs\",\"name\":\"plt\",\"visitid\":\"ABCDEFG1234\",\"value\":\"90\",\"date\":\"2021-07-01\",\"timestamp\":\"2021-07-01 00:00:00\",\"value_text_sentences\":[\"90.0\"],\"orderTimestamp\":1444060800000},{\"type\":\"labs\",\"name\":\"plt\",\"visitid\":\"ABCDEFG1234\",\"value\":\"87\",\"date\":\"2021-07-02\",\"timestamp\":\"2021-07-02 00:00:00\",\"value_text_sentences\":[\"87.0\"],\"orderTimestamp\":1444147200000},{\"type\":\"labs\",\"name\":\"plt\",\"visitid\":\"ABCDEFG1234\",\"value\":\"87\",\"date\":\"2021-07-02\",\"timestamp\":\"2021-07-02 00:00:00\",\"value_text_sentences\":[\"87.0\"],\"orderTimestamp\":1444147200000},{\"type\":\"labs\",\"name\":\"plt\",\"visitid\":\"ABCDEFG1234\",\"value\":\"86\",\"date\":\"2021-07-03\",\"timestamp\":\"2021-07-03 00:00:00\",\"value_text_sentences\":[\"86.0\"],\"orderTimestamp\":1444233600000},{\"type\":\"labs\",\"name\":\"plt\",\"visitid\":\"ABCDEFG1234\",\"value\":\"92\",\"date\":\"2021-07-04\",\"timestamp\":\"2021-07-04 00:00:00\",\"value_text_sentences\":[\"92.0\"],\"orderTimestamp\":1444320000000},{\"type\":\"labs\",\"name\":\"plt\",\"visitid\":\"ABCDEFG1234\",\"value\":\"97\",\"date\":\"2021-07-04\",\"timestamp\":\"2021-07-04 00:00:00\",\"value_text_sentences\":[\"97.0\"],\"orderTimestamp\":1444320000000},{\"type\":\"labs\",\"name\":\"plt\",\"visitid\":\"ABCDEFG1234\",\"value\":\"118\",\"date\":\"2021-07-05\",\"timestamp\":\"2021-07-05 00:00:00\",\"value_text_sentences\":[\"118.0\"],\"orderTimestamp\":1444406400000},{\"type\":\"labs\",\"name\":\"plt\",\"visitid\":\"ABCDEFG1234\",\"value\":\"116\",\"date\":\"2021-07-06\",\"timestamp\":\"2021-07-06 00:00:00\",\"value_text_sentences\":[\"116.0\"],\"orderTimestamp\":1444492800000},{\"type\":\"labs\",\"name\":\"plt\",\"visitid\":\"ABCDEFG1234\",\"value\":\"134\",\"date\":\"2021-07-06\",\"timestamp\":\"2021-07-06 00:00:00\",\"value_text_sentences\":[\"134.0\"],\"orderTimestamp\":1444492800000},{\"type\":\"labs\",\"name\":\"plt\",\"visitid\":\"ABCDEFG1234\",\"value\":\"134\",\"date\":\"2021-07-07\",\"timestamp\":\"2021-07-07 00:00:00\",\"value_text_sentences\":[\"134.0\"],\"orderTimestamp\":1444579200000},{\"type\":\"labs\",\"name\":\"plt\",\"visitid\":\"ABCDEFG1234\",\"value\":\"112\",\"date\":\"2021-07-08\",\"timestamp\":\"2021-07-08 00:00:00\",\"value_text_sentences\":[\"112.0\"],\"orderTimestamp\":1444665600000},{\"type\":\"labs\",\"name\":\"plt\",\"visitid\":\"ABCDEFG1234\",\"value\":\"139\",\"date\":\"2021-07-08\",\"timestamp\":\"2021-07-08 00:00:00\",\"value_text_sentences\":[\"139.0\"],\"orderTimestamp\":1444665600000}]]},{\"type\":\"single\",\"hide\":false,\"triggeredAt\":[],\"details\":[[{\"type\":\"notes\",\"name\":\"plan\",\"visitid\":\"ABCDEFG1234\",\"value\":\"\",\"date\":\"2021-06-30\",\"timestamp\":\"2021-06-30 00:00:00\",\"highlight\":{\"value_text_sentences\":[\"Anesthesia type: MAC Mental status (LOC assessment): Cognitive Cognitive/Neuro/Behavioral WDL: WDL arousability level of consciousness mood/behavior orientation speech (06/30/21 1337) Level of Consciousness: alert (06/30/21 1337) Arousal Level: opens eyes spontaneously arouses to voice (06/30/21 1337) Orientation: situation place (06/30/21 1337) Speech: clear (06/30/21 1337) Mood/Behavior: cooperative calm (06/30/21 1337) Additional Documentation: CAM (Confusion Assessment Method) (Group) (06/29/21 2300) Vitals Vital Signs Row Name 06/29/21 1600 06/30/21 0000 06/30/21 0900 Vital Signs Pulse 98 98 103 BP 142/89 150/84 143/89 Resp 18 18 18 Temp 97.5 °F (36.4 °C) 97.8 °F (36.6 °C) 98 °F (36.7 °C) SpO2 97 % 97 % 95 % Row Name 06/30/21 1325 06/30/21 1330 06/30/21 1340 Vital Signs Pulse 107 101 95 BP 121/73 122/80 137/86 Resp 14 16 16 Temp 97.9 °F (36.6 °C)   SpO2 93 % 98 % 98 % Row Name 06/30/21 129884 1355 Vital Signs Pulse 98 BP 141/85 Resp 18 Temp 98.1 °F (36.7 °C) SpO2 96 % Oxygen Therapy: Device (Oxygen Therapy): room air (06/30/21 1355) O2 Flow Rate (L/min): 2 L/min (06/30/21 1340) Vent Settings: Pain Assessment Preferred Pain Scale: number (Numeric Rating Pain Scale) (06/29/21 2020) Pain Side/Orientation: generalized (06/28/21 1752) Pain Location: back (06/28/21 1752) I & O: No intake/output data recorded. LDAs/Implants Lines with Linked Medications Peripheral IV (Adult) 06/27/21 Left Forearm Order Name Port Current Infusion Rate [MAR Hold] heparin 25 000 unit/250 mL in D5W infusion Start: 06/28/21 0955 potassium chloride 10 mEq in 100 mL (ISO-OSMOTIC) IVPB 100 mL/hr Start: 06/29/21 1200 [MAR Hold] hydrocortisone (PF) injection 100 mg/2 mL 75 mg Start: 06/29/21 2200 Peripheral IV (Adult) 06/29/21 Left Forearm ** No Currently Infusing Medications ** Patient Lines/Drains/Airways Status Active Central Venous Catheter Line / Line / Peripherally Inserted Central Catheter Line / Peripheral Intravenous Line / Drain / Airway / Intraosseous Line / Epidural Line / Arterial Line / Wound / Pressure Ulcer / Nasogastric/Orogastric Tube / Hemodialysis Catheter / Umbilical Venous Catheter / Foley Catheter / Intrauterine Pressure Catheter Name Placement date Placement time Site Days Peripheral IV (Adult) 06/27/21 Left Forearm 06/27/21 0610 Forearm 3 Peripheral IV (Adult) 06/29/21 Left Forearm 06/29/21  Forearm 1 Rash 06/22/21 0008 other (see comments) midline perineum other (see comments) 06/22/21 0008 8 Wound (Adult Obstetrics Pediatric)- NOT for mucosal pressure injury 06/21/21 2000 other (see comments) midline sacral spine pressure injury 06/21/21 2000 8 Wound (Adult Obstetrics Pediatric)- NOT for mucosal pressure injury 06/21/21 2000 Right 129885 posterior buttocks pressure injury 06/21/21 2000 8 Incision 06/30/21 urethral meatus 06/30/21 1306 less than 1 Estimated Blood Loss: Sequential Compression Device (SCDs) on/off: VTE Prevention/Management: other (see comments) (pt is on heparin gtt <span class='highlighted'>scd</span> held  aware) (06/29/21 0944) Treatment Administered: levETIRAcetam tablet 500 mg ( oral Dose Auto Held 07/6/21 2100) insulin lispro (HumaLOG) injection (rapid-acting) 0-6 unit ( subcutaneous Dose Auto Held 07/6/21 1700) insulin lispro (HumaLOG) injection (rapid-acting) 0-4 unit ( subcutaneous Dose Auto Held 07/6/21 2200) dextrose 50 % intravenous solution 50 mL ( intravenous MAR Hold 06/30/21 1134) glucagon (human recombinant) 1 mg injection 1 mg ( intramuscular MAR Hold 06/30/21 1134) nystatin 100 000 unit/gram cream ( topical MAR Hold 06/30/21 1134) atovaquone 150 mg/mL oral suspension 1 500 mg ( oral Dose Auto Held 07/7/21 1800) levothyroxine tablet 137 MCG ( oral Dose Auto Held 07/7/21 0600) levothyroxine tablet 150 MCG ( oral Dose Auto Held 07/8/21 0600) ondansetron (PF) 2 mg/mL injection 4 mg (4 mg intravenous Given 06/30/21 1248) heparin 25 000 unit/250 mL in D5W infusion ( intravenous MAR Hold 06/30/21 1134) heparin (for IV bolus) 5 000 unit/mL injection 3 250 unit ( intravenous MAR Hold 06/30/21 1134) And heparin (for IV bolus) 5 000 unit/mL injection 6 500 unit ( intravenous MAR Hold 06/30/21 1134) hydrocortisone (PF) injection 100 mg/2 mL 75 mg ( intravenous Dose Auto Held 07/9/21 2200) meropenem 500 mg in sterile water for injection 10 mL IV Push (has no administration in time range) fentaNYL (PF) 50 mcg/mL injection 25 MCG (has no administration in time range) fentaNYL (PF) 50 mcg/mL injection 50 MCG (has no administration in time range) ondansetron (PF) 2 mg/mL injection 4 mg (has no administration in time range) prochlorperazine 5 mg/mL injection 5 mg (has no 129886 administration in time range) sodium chloride 0.9 % bolus 1 000 mL (0 mL intravenous Stopped 06/21/21 1318) sodium chloride 0.9 % bolus 1 000 mL (0 mL intravenous Stopped 06/21/21 1313) acetaminophen tablet 975 mg (975 mg oral Given 06/21/21 1406) meropenem 500 mg in sterile water for injection 10 mL IV Push (500 mg intravenous Given 06/21/21 1407) vancomycin 1 000 mg in dextrose 5 % 250 mL IVPB-MBP (1 000 mg intravenous Given 06/21/21 1407) iohexoL 350 mg iodine/mL injection 100 mL (100 mL intravenous Given 06/21/21 1355) sodium chloride 0.9 % bolus 1 000 mL (0 mL intravenous Stopped 06/21/21 1553) vancomycin 1 000 mg in dextrose 5 % 250 mL IVPB-MBP (1 000 mg intravenous Given 06/21/21 2240) meropenem 500 mg in sterile water for injection 10 mL IV Push (500 mg intravenous Given 06/21/21 2115) meropenem 500 mg in sterile water for injection 10 mL IV Push (500 mg intravenous Given 06/29/21 1238) potassium chloride 10 mEq in 100 mL (ISO-OSMOTIC) IVPB (10 mEq intravenous Given 06/22/21 2219) potassium chloride 10 mEq in 100 mL (ISO-OSMOTIC) IVPB (10 mEq intravenous Given 06/23/21 2236) potassium chloride ER tablet 20 mEq (20 mEq oral Given 06/24/21 0611) potassium chloride ER tablet 20 mEq (20 mEq oral Given 06/25/21 0808) potassium chloride ER tablet 20 mEq (20 mEq oral Given 06/30/21 0028) potassium chloride 10 mEq in 100 mL (ISO-OSMOTIC) IVPB (10 mEq intravenous Given 06/29/21 1716) Blood Transfusion Record Product Unit Status Volume Start End Transfuse RBC:Transfusion Rate: As fast as possible W2004 21 398456 V-E0332V00 Completed 06/26/21 2317 06/26/21 1832 06/26/21 2135 Additional Documentation: I  RN gave report to  RN on 06/30/2021 1:59 PM 27218  Hospital - Hospitalist Department DAILY MEDICINE PROGRESS NOTE The patient's medical records have been reviewed.Admit Date: 06/21/2021 Subjective: Translator Used: lung cancer stage IV with mets to the brain and liver recently diagnosed with bilateral PE on therapeutic lovenox admitted for sepsis POA secondary to UTI.\"]},\"orderTimestamp\":1443974400000}]]},{\"type\":\"single\",\"hide\":false,\"triggeredAt\":[],\"details\":[[{\"type\":\"notes\",\"name\":\"plan\",\"visitid\":\"ABCDEFG1234\",\"value\":\"\",\"date\":\"2021-06-24\",\"timestamp\":\"2021-06-24 00:00:00\",\"highlight\":{\"value_text_sentences\":[\"female with PMHx lung cancer stage IV with mets to the brain and liver recently diagnosed with bilateral PE on therapeutic lovenox admitted for sepsis POA secondary to UTI. #Severe sepsis POA secondary to UTI SIRS +2 (BP WBC) + urinary source UA noticed urine cx noted sensitive to meropenem ID recs aprpreciated continue broad spectrum abx Lactic acid wnl IV fluids as needed Tylenol 650mg q6h PRN for fever Blood cx NGTD Stress dose steroids taper as infection resolves #Suspected hemorrhagic cystitis IVF as needed Urology consulted recs appreciated Monitor CBC q12h Active T&S will tx if Hgb <7 Continue IV abx #PE On therapeutic lovenox will hold in setting of bleed TTE with normal LV/RV function Monitor on telemetry #Metastatic lung cancer to brain and liver Supportive care Received chemo x1 was to resume this month but LFTs elevated Follows at  Resume chemo after d/c once cleared by oncology #DM Hold metformin ISS HbA1c Goal f/s 140-200 #Thyroid cancer Supportive care GI ppx: not indicated DVT ppx: <span class='highlighted'>SCDs</span> Foley: no Code status: FULL Dispo: pending clinical improvement Time spent on counseling/coordination of care: 35 minutes 06/24/2021 6:17 PM\"]},\"orderTimestamp\":1443456000000},{\"type\":\"notes\",\"name\":\"plan\",\"visitid\":\"ABCDEFG1234\",\"value\":\"\",\"date\":\"2021-06-25\",\"timestamp\":\"2021-06-25 00:00:00\",\"highlight\":{\"value_text_sentences\":[\"116023 POC reviewed IV fluids IV abx <span class='highlighted'>SCDs</span> for VTE prophylaxis.Hourly rounding implemented.\",\"female with PMHx lung cancer stage IV with mets to the brain and liver recently diagnosed with bilateral PE on therapeutic lovenox admitted for sepsis POA secondary to UTI. #Severe sepsis POA secondary to UTI SIRS +2 (BP WBC) + urinary source UA noticed urine cx noted sensitive to meropenem ID recs aprpreciated continue broad spectrum abx Lactic acid wnl IV fluids as needed Tylenol 650mg q6h PRN for fever Blood cx NGTD Stress dose steroids taper as infection resolves #Suspected hemorrhagic cystitis IVF as needed Urology consulted recs appreciated Monitor CBC q12h Active T&S will tx if Hgb <7 Continue IV abx # recent bilateral PE At home On therapeutic lovenox will hold in setting of active gross hematuria TTE with normal LV/RV function Patient at high risk for DVT/PE given her Hx and active cancer If hematuria improves then would attempt IV heparin drip If hematuria not improved in next 24 hours then would order IVC filter and discuss with her oncology team at  Monitor on telemetry #Metastatic lung cancer to brain and liver Supportive care Received chemo x1 was to resume this month but LFTs elevated Follows at  Resume chemo after d/c once cleared by oncology # sacral and a right buttock pressure ulcer present on admission - appreciate skin clinician consult #DM Hold metformin ISS HbA1c Goal f/s 140-200 #Thyroid cancer Supportive care GI ppx: not indicated DVT ppx: <span class='highlighted'>SCDs</span> Foley: no Code status: FULL Dispo: pending clinical improvement Time spent on counseling/coordination of care: 35 minutes Patient Vitals for the past 24 hrs: BP Temp Temp src Pulse Resp SpO2 06/25/21 27794 1231 112/70 97.7 °F (36.5 °C) Oral 110 18 95 % 06/25/21 0800 129/83 97.9 °F (36.6 °C) Oral 100 18 96 % 06/25/21 0400 115/74 97.9 °F (36.6 °C) Oral 102 18 95 % 06/24/21 2339 114/72 97.8 °F (36.6 °C) Oral 113 18 96 % 06/24/21 2000 123/83 97.6 °F (36.4 °C) Oral 107 18 94 % 06/24/21 1632 124/86 97.6 °F (36.4 °C) Oral 101 19 94 % BP: (112-129)/(70-86) 112/70 Pulse: [100-113] 110 Resp: [18-19] 18 SpO2: [94 %-96 %] 95 % Temp: [97.6 °F (36.4 °C)-97.9 °F (36.6 °C)] 97.7 °F (36.5 °C) (06/24 1511-06/25 1231) Data Reviewed Recent Labs 06/23/21 1320 06/24/21 0758 06/24/21 1542 06/25/21 0825 WBC 6.4 6.6 6.0 5.6 HGB 9.3* 8.3* 8.1* 7.9* HCT 27.3* 25.4* 24.5* 24.8* PLT 91* 87* 84* 94* MCV 82.7 83.8 84.5 87.0 RDW 20.1* 21.2* 21.4* 22.0* Recent Labs 06/23/21 0538 06/24/21 0758 06/25/21 0825 NA 139 139 139 K 2.5* 3.0* 3.2* CL 108* 108* 108* CO2 18* 21* 22* BUN 17 17 16 CREATININE 0.5* 0.5* 0.5* Recent Labs 06/23/21 0538 06/24/21 0758 06/25/21 0825 GLU 142* 111* 116* Recent labs Lab Units 06/24/21 0758 06/21/21 1242 06/18/21 0730 06/17/21 2352 ALBUMIN GM/DL 2.7* 3.5 3.6 3.9 BILIRUBIN TOTAL MG/DL 4.8* 2.5* 0.9 1.0 BILIRUBIN DIRECT MG/DL 3.6* 1.4* 0.3* 0.3* ALK PHOS U/L 314* 269* 114 116 ALT U/L 1 757* 1 857* 382* 318* AST U/L 704* 1 154* 157* 133* PROTEIN TOTAL GM/DL 4.2* 5.2* 5.3* 5.8 No results for input(s): INR in the last 72 hours.Microbiology Results (last 7 days) Procedure Component Value Units Date/Time URINE STANDARD CULTURE [1251240043] (Abnormal) (Susceptibility) Collected: 06/21/21 1406 Lab Status: Final result Specimen: Urine Clean-Catch Updated: 06/23/21 1141 Urine Culture >100 000 CFU/mL Escherichia coli Susceptibility Escherichia coli (1) Antibiotic Interpretation MIC Method Status Amikacin Sensitive <=16 ug/ml MIC/INTERPRETATION Final Ampicillin Resistant >16 ug/ml 27795 MIC/INTERPRETATION Final Ampicillin/Sulbactam Intermediate 16/8 ug/ml MIC/INTERPRETATION Final Aztreonam Sensitive <=4 ug/ml MIC/INTERPRETATION Final Cefazolin Sensitive 8 ug/ml MIC/INTERPRETATION Final Cefepime Sensitive <=2 ug/ml MIC/INTERPRETATION Final Cefotaxime Sensitive <=2 ug/ml MIC/INTERPRETATION Final Ceftazidime Sensitive <=1 ug/ml MIC/INTERPRETATION Final Ceftriaxone Sensitive <=1 ug/ml MIC/INTERPRETATION Final Cefuroxime Sensitive <=4 ug/ml MIC/INTERPRETATION Final Ciprofloxacin Resistant >2 ug/ml MIC/INTERPRETATION Final Ertapenem Sensitive <=0.5 ug/ml MIC/INTERPRETATION Final Gentamicin Resistant >8 ug/ml MIC/INTERPRETATION Final Levofloxacin Resistant >4 ug/ml MIC/INTERPRETATION Final Meropenem Sensitive <=1 ug/ml MIC/INTERPRETATION Final Nitrofurantoin Sensitive <=32 ug/ml MIC/INTERPRETATION Final Piperacillin/Tazobactam Sensitive <=16 ug/ml MIC/INTERPRETATION Final Tetracycline Resistant >8 ug/ml MIC/INTERPRETATION Final Tobramycin Intermediate 8 ug/ml MIC/INTERPRETATION Final Trimethoprim/Sulfamethoxazole Resistant >2/38 ug/ml MIC/INTERPRETATION Final SARS-CoV-2 (Asymptomatic) [1251240026] (Normal) Collected: 06/21/21 1243 Lab Status: Final result Specimen: Swab from Nasopharyngeal Updated: 06/21/21 1340 SARS-CoV-2 (COVID 19) by NAAT Negative Blood Bacteriology Culture (1st Set) [1251240019] Collected: 06/21/21 1242 Lab Status: Preliminary result Specimen: Blood Peripheral Updated: 06/25/21 1316 Blood Culture No growth after 4 days Blood Bacteriology Culture (2nd Set) [1251240020] Collected: 06/21/21 1242 Lab Status: Preliminary result Specimen: Blood Peripheral Updated: 06/25/21 1316 Blood Culture No growth after 4 days HEPATITIS PROFILE [1251240047] (Normal) Collected: 06/21/21 1242 Lab Status: Final result Specimen: Blood Updated: 06/21/21 1640 HBSAG Non Reactive HBSAB Non 27797 Reactive HAVAB Nonreactive HBC Nonreactive HCV Nonreactive Imaging: Imaging results: ** No results found for the last 24 hours.\"]},\"orderTimestamp\":1443542400000},{\"type\":\"notes\",\"name\":\"plan\",\"visitid\":\"ABCDEFG1234\",\"value\":\"\",\"date\":\"2021-06-26\",\"timestamp\":\"2021-06-26 00:00:00\",\"highlight\":{\"value_text_sentences\":[\"#Severe sepsis POA secondary to UTI SIRS +2 (BP WBC) + urinary source UA noticed urine cx noted sensitive to meropenem ID recs aprpreciated continue broad spectrum abx Lactic acid wnl IV fluids Tylenol 650mg q6h PRN for fever Blood cx NGTD Stress dose steroids taper as infection resolves WBC improved Afebrile now #Suspected hemorrhagic cystitis IVF Urology consulted recs appreciated no intervention at this time Monitor CBC q12h Active T&S will tx if Hgb <7 Continue IV abx # recent bilateral PE At home On therapeutic lovenox 27642 will hold in setting of active gross hematuria TTE with normal LV/RV function Patient at high risk for DVT/PE given her Hx and active cancer - Gross hematuria/ acute blood loss anemia not candidate for AC at this time patient is at high risk for DVT/PE given her Hx and ongoing malignancy I offered IVC filter to be done hopefully Monday 06/27/21 patient agrees and understands. I updated  nurse to convey that to hematologist/oncologist at  #Metastatic lung cancer to brain and liver Supportive care Received chemo x1 was to resume this month but LFTs elevated Follows at  Re-check LFT Resume chemo after d/c once cleared by oncology # sacral and a right buttock pressure ulcer present on admission - appreciate skin clinician consult #DM Hold metformin ISS HbA1c Goal f/s 140-200 #Thyroid cancer Supportive care GI ppx: not indicated DVT ppx: <span class='highlighted'>SCDs</span> Foley: no Code status: FULL Dispo: pending clinical improvement Time spent on counseling/coordination of care: 35 minutes Patient Vitals for the past 24 hrs: BP Temp Temp src Pulse Resp SpO2 06/26/21 1221 112/78   120  96 % 06/26/21 1220 112/78 97 °F (36.1 °C) Axillary 120 24 96 % 06/26/21 1213 (!) 81/59   (!) 127  99 % 06/26/21 1130 136/78 98 °F (36.7 °C) Oral 111 19 94 % 06/26/21 0812 127/81 97.7 °F (36.5 °C) Oral 111 20 95 % 06/26/21 0400 119/77 97.7 °F (36.5 °C) Oral 100 18 98 % 06/26/21 0000 120/72 97.9 °F (36.6 °C) Oral 100 18 97 % 06/25/21 2000 133/79 97.8 °F (36.6 °C) Oral 114 18 96 % 06/25/21 1541 106/67 97.7 °F (36.5 °C) Oral 117 18 95 % BP: (81-136)/(59-81) 112/78 Pulse: [100-127] 120 Resp: [18-24] 24 SpO2: [94 %-99 %] 96 % Temp: [97 °F (36.1 °C)-98 °F (36.7 °C)] 97 °F (36.1 °C) (06/25 1318-06/26 1221) Data Reviewed Recent Labs 06/24/21 0758 06/24/21 1542 06/25/21 0825 06/26/21 0721 WBC 6.6 6.0 5.6 6.1 HGB 8.3* 8.1* 7.9* 7.1* HCT 27631 will hold in setting of active gross hematuria TTE with normal LV/RV function Patient at high risk for DVT/PE given her Hx and active cancer - Gross hematuria/ acute blood loss anemia not candidate for AC at this time patient is at high risk for DVT/PE given her Hx and ongoing malignancy I offered IVC filter to be done hopefully Monday 06/27/21 patient agrees and understands.I updated  nurse to convey that to hematologist/oncologist at  #Metastatic lung cancer to brain and liver Supportive care Received chemo x1 was to resume this month but LFTs elevated Follows at  Re-check LFT Resume chemo after d/c once cleared by oncology # Abnormal LFT and jaundice due to liver metastasis - trend LFT # sacral and a right buttock pressure ulcer present on admission - appreciate skin clinician consult #DM Hold metformin ISS HbA1c Goal f/s 140-200 #Thyroid cancer Supportive care GI ppx: not indicated DVT ppx: SCDs Foley: no Code status: FULL Dispo: pending clinical improvement Time spent on counseling/coordination of care: 35 minutes Patient Vitals for the past 24 hrs: BP Temp Temp src Pulse Resp SpO2 06/26/21 1221 112/78   120  96 % 06/26/21 1220 112/78 97 °F (36.1 °C) Axillary 120 24 96 % 06/26/21 1213 (!) 81/59   (!) 127  99 % 06/26/21 1130 136/78 98 °F (36.7 °C) Oral 111 19 94 % 06/26/21 0812 127/81 97.7 °F (36.5 °C) Oral 111 20 95 % 06/26/21 0400 119/77 97.7 °F (36.5 °C) Oral 100 18 98 % 06/26/21 0000 120/72 97.9 °F (36.6 °C) Oral 100 18 97 % 06/25/21 2000 133/79 97.8 °F (36.6 °C) Oral 114 18 96 % 06/25/21 1541 106/67 97.7 °F (36.5 °C) Oral 117 18 95 % BP: (81-136)/(59-81) 112/78 Pulse: [100-127] 120 Resp: [18-24] 24 SpO2: [94 %-99 %] 96 % Temp: [97 °F (36.1 °C)-98 °F (36.7 °C)] 97 °F (36.1 °C) (06/25 1318-06/26 1221) Data Reviewed Recent Labs 06/24/21 0758 06/24/21 1542 06/25/21 0825 75402 06/26/21 0721 WBC 6.6 6.0 5.6 6.1 HGB 8.3* 8.1* 7.9* 7.1* HCT 25.4* 24.5* 24.8* 22.2* PLT 87* 84* 94* 96* MCV 83.8 84.5 87.0 87.1 RDW 21.2* 21.4* 22.0* 22.6* Recent Labs 06/24/21 0758 06/25/21 0825 06/26/21 0721 NA 139 139 139 K 3.0* 3.2* 3.5 CL 108* 108* 108* CO2 21* 22* 21* BUN 17 16 19 CREATININE 0.5* 0.5* 0.5* Recent Labs 06/24/21 0758 06/25/21 0825 06/26/21 0721 GLU 111* 116* 145* Recent labs Lab Units 06/24/21 0758 06/21/21 1242 06/18/21 0730 06/17/21 2352 ALBUMIN GM/DL 2.7* 3.5 3.6 3.9 BILIRUBIN TOTAL MG/DL 4.8* 2.5* 0.9 1.0 BILIRUBIN DIRECT MG/DL 3.6* 1.4* 0.3* 0.3* ALK PHOS U/L 314* 269* 114 116 ALT U/L 1 757* 1 857* 382* 318* AST U/L 704* 1 154* 157* 133* PROTEIN TOTAL GM/DL 4.2* 5.2* 5.3* 5.8 No results for input(s): INR in the last 72 hours.\",\"I updated  nurse to convey that to hematologist/oncologist at  #Metastatic lung cancer to brain and liver Supportive care Received chemo x1 was to resume this month but LFTs elevated Follows at  Re-check LFT Resume chemo after d/c once cleared by oncology # sacral and a right buttock pressure ulcer present on admission - appreciate skin clinician consult #DM Hold metformin ISS HbA1c Goal f/s 140-200 #Thyroid cancer Supportive care GI ppx: not indicated DVT ppx: SCDs Foley: no Code status: FULL Dispo: pending clinical improvement Time spent on counseling/coordination of care: 35 minutes Patient Vitals for the past 24 hrs: BP Temp Temp src Pulse Resp SpO2 06/26/21 1221 112/78   120  96 % 06/26/21 1220 112/78 97 °F (36.1 °C) Axillary 120 24 96 % 06/26/21 1213 (!) 81/59   (!) 127  99 % 06/26/21 1130 136/78 98 °F (36.7 °C) Oral 111 19 94 % 06/26/21 0812 127/81 97.7 °F (36.5 °C) Oral 111 20 95 % 06/26/21 0400 119/77 97.7 °F (36.5 °C) Oral 100 18 98 % 06/26/21 0000 120/72 97.9 °F (36.6 °C) Oral 100 18 97 % 06/25/21 2000 133/79 97.8 °F (36.6 °C) Oral 114 18 96 % 06/25/21 1541 106/67 97.7 °F (36.5 °C) Oral 117 18 95 % BP: (81-136)/(59-81) 112/78 Pulse: [100-127] 120 Resp: [18-24] 24 SpO2: [94 %-99 %] 96 % Temp: [97 °F (36.1 °C)-98 °F (36.7 °C)] 97 °F (36.1 °C) (06/25 1318-06/26 1221) Data Reviewed Recent Labs 06/24/21 0758 06/24/21 1542 06/25/21 0825 06/26/21 0721 WBC 6.6 6.0 5.6 6.1 HGB 8.3* 8.1* 7.9* 7.1* HCT 27631 will hold in setting of active gross hematuria TTE with normal LV/RV function Patient at high risk for DVT/PE given her Hx and active cancer - Gross hematuria/ acute blood loss anemia not candidate for AC at this time patient is at high risk for DVT/PE given her Hx and ongoing malignancy I offered IVC filter to be done hopefully Monday 06/27/21 patient agrees and understands. I updated  nurse to convey that to hematologist/oncologist at  #Metastatic lung cancer to brain and liver Supportive care Received chemo x1 was to resume this month but LFTs elevated Follows at  Re-check LFT Resume chemo after d/c once cleared by oncology # Abnormal LFT and jaundice due to liver metastasis - trend LFT # sacral and a right buttock pressure ulcer present on admission - appreciate skin clinician consult #DM Hold metformin ISS HbA1c Goal f/s 140-200 #Thyroid cancer Supportive care GI ppx: not indicated DVT ppx: <span class='highlighted'>SCDs</span> Foley: no Code status: FULL Dispo: pending clinical improvement Time spent on counseling/coordination of care: 35 minutes Patient Vitals for the past 24 hrs: BP Temp Temp src Pulse Resp SpO2 06/26/21 1221 112/78   120  96 % 06/26/21 1220 112/78 97 °F (36.1 °C) Axillary 120 24 96 % 06/26/21 1213 (!) 81/59   (!) 127  99 % 06/26/21 1130 136/78 98 °F (36.7 °C) Oral 111 19 94 % 06/26/21 0812 127/81 97.7 °F (36.5 °C) Oral 111 20 95 % 06/26/21 0400 119/77 97.7 °F (36.5 °C) Oral 100 18 98 % 06/26/21 0000 120/72 97.9 °F (36.6 °C) Oral 100 18 97 % 06/25/21 2000 133/79 97.8 °F (36.6 °C) Oral 114 18 96 % 06/25/21 1541 106/67 97.7 °F (36.5 °C) Oral 117 18 95 % BP: (81-136)/(59-81) 112/78 Pulse: [100-127] 120 Resp: [18-24] 24 SpO2: [94 %-99 %] 96 % Temp: [97 °F (36.1 °C)-98 °F (36.7 °C)] 97 °F (36.1 °C) (06/25 1318-06/26 1221) Data Reviewed Recent Labs 06/24/21 0758 06/24/21 1542 06/25/21 0825 75402 06/26/21 0721 WBC 6.6 6.0 5.6 6.1 HGB 8.3* 8.1* 7.9* 7.1* HCT 25.4* 24.5* 24.8* 22.2* PLT 87* 84* 94* 96* MCV 83.8 84.5 87.0 87.1 RDW 21.2* 21.4* 22.0* 22.6* Recent Labs 06/24/21 0758 06/25/21 0825 06/26/21 0721 NA 139 139 139 K 3.0* 3.2* 3.5 CL 108* 108* 108* CO2 21* 22* 21* BUN 17 16 19 CREATININE 0.5* 0.5* 0.5* Recent Labs 06/24/21 0758 06/25/21 0825 06/26/21 0721 GLU 111* 116* 145* Recent labs Lab Units 06/24/21 0758 06/21/21 1242 06/18/21 0730 06/17/21 2352 ALBUMIN GM/DL 2.7* 3.5 3.6 3.9 BILIRUBIN TOTAL MG/DL 4.8* 2.5* 0.9 1.0 BILIRUBIN DIRECT MG/DL 3.6* 1.4* 0.3* 0.3* ALK PHOS U/L 314* 269* 114 116 ALT U/L 1 757* 1 857* 382* 318* AST U/L 704* 1 154* 157* 133* PROTEIN TOTAL GM/DL 4.2* 5.2* 5.3* 5.8 No results for input(s): INR in the last 72 hours.Microbiology Results (last 7 days) Procedure Component Value Units Date/Time URINE STANDARD CULTURE [1251240043] (Abnormal) (Susceptibility) Collected: 06/21/21 1406 Lab Status: Final result Specimen: Urine Clean-Catch Updated: 06/23/21 1141 Urine Culture >100 000 CFU/mL Escherichia coli Susceptibility Escherichia coli (1) Antibiotic Interpretation MIC Method Status Amikacin Sensitive <=16 ug/ml MIC/INTERPRETATION Final Ampicillin Resistant >16 ug/ml MIC/INTERPRETATION Final Ampicillin/Sulbactam Intermediate 16/8 ug/ml MIC/INTERPRETATION Final Aztreonam Sensitive <=4 ug/ml MIC/INTERPRETATION Final Cefazolin Sensitive 8 ug/ml MIC/INTERPRETATION Final Cefepime Sensitive <=2 ug/ml MIC/INTERPRETATION Final Cefotaxime Sensitive <=2 ug/ml MIC/INTERPRETATION Final Ceftazidime Sensitive <=1 ug/ml MIC/INTERPRETATION Final Ceftriaxone Sensitive <=1 ug/ml MIC/INTERPRETATION Final Cefuroxime Sensitive <=4 ug/ml MIC/INTERPRETATION Final Ciprofloxacin Resistant >2 ug/ml MIC/INTERPRETATION Final Ertapenem Sensitive <=0.5 ug/ml 75413 25.4* 24.5* 24.8* 22.2* PLT 87* 84* 94* 96* MCV 83.8 84.5 87.0 87.1 RDW 21.2* 21.4* 22.0* 22.6* Recent Labs 06/24/21 0758 06/25/21 0825 06/26/21 0721 NA 139 139 139 K 3.0* 3.2* 3.5 CL 108* 108* 108* CO2 21* 22* 21* BUN 17 16 19 CREATININE 0.5* 0.5* 0.5* Recent Labs 06/24/21 0758 06/25/21 0825 06/26/21 0721 GLU 111* 116* 145* Recent labs Lab Units 06/24/21 0758 06/21/21 1242 06/18/21 0730 06/17/21 2352 ALBUMIN GM/DL 2.7* 3.5 3.6 3.9 BILIRUBIN TOTAL MG/DL 4.8* 2.5* 0.9 1.0 BILIRUBIN DIRECT MG/DL 3.6* 1.4* 0.3* 0.3* ALK PHOS U/L 314* 269* 114 116 ALT U/L 1 757* 1 857* 382* 318* AST U/L 704* 1 154* 157* 133* PROTEIN TOTAL GM/DL 4.2* 5.2* 5.3* 5.8 No results for input(s): INR in the last 72 hours.\",\"Will initiate CBI for now and monitor progression of hematuria. - V: Reviewed afebrile tachycardic O2 WNL - Labs: reviewed 27533 acute anemia likely blood loss anemia with thrombocytopenia otherwise WNL - As above will plan to initiate CBI and monitor hematuria for now as patient is high risk candidate for surgical intervention at this time - Recommend continue to monitor H/H and transfuse PRN - Continue adequate pain control - Encourage Incentive Spirometry use OOB and ambulating - DVT ppx: <span class='highlighted'>SCDs</span> AC held for anemia and hematuria Discussed with Dr. endorsed to Dr.\"]},\"orderTimestamp\":1443628800000},{\"type\":\"notes\",\"name\":\"progress_note\",\"visitid\":\"ABCDEFG1234\",\"value\":\"\",\"date\":\"2021-06-27\",\"timestamp\":\"2021-06-27 00:00:00\",\"highlight\":{\"value_text_sentences\":[\"Patient hoping for resolution of hematuria and trial of heparin drip once ok with GU patient understands and accepts risks for possible recurrent PE. I updated  nurse to convey that to hematologist/oncologist at  #Metastatic lung cancer to brain and liver Supportive care Received chemo x1 was to resume this month but LFTs elevated Follows at  Re-check LFT Resume chemo after d/c once cleared by oncology palliative care on board # Acute liver injury / Abnormal LFT and jaundice probably due to chemo - trend 27789 LFT-->improving since admission # sacral and a right buttock pressure ulcer present on admission - appreciate skin clinician consult #DM Hold metformin ISS HbA1c Goal f/s 140-200 #Thyroid cancer Supportive care GI ppx: not indicated DVT ppx: <span class='highlighted'>SCDs</span> Foley: no Code status: FULL Dispo: pending clinical improvement Time spent on counseling/coordination of care: 35 minutes Patient Vitals for the past 24 hrs: BP Temp Temp src Pulse Resp SpO2 06/27/21 0758 (!) 145/89 98.2 °F (36.8 °C) Oral 98 20 94 % 06/27/21 0500 (!) 141/77      06/27/21 0400 (!) 151/88 97.7 °F (36.5 °C) Oral 96 20 96 % 06/27/21 0000 (!) 143/86 97.9 °F (36.6 °C) Oral 99 20 96 % 06/26/21 2135 135/79 98.6 °F (37 °C) Oral 86 20  06/26/21 2000 140/83 98 °F (36.7 °C) Oral 114 20 95 % 06/26/21 1847 139/83 97.9 °F (36.6 °C) Oral 115 20 95 % 06/26/21 1832 127/81 97.6 °F (36.4 °C)  113 20  06/26/21 1613 134/82 97.9 °F (36.6 °C) Oral 108 20 96 % BP: (127-151)/(77-89) 145/89 Pulse: [86-115] 98 Resp: [20] 20 SpO2: [94 %-96 %] 94 % Temp: [97.6 °F (36.4 °C)-98.6 °F (37 °C)] 98.2 °F (36.8 °C) (06/26 1224-06/27 0758) Data Reviewed Recent Labs 06/26/21 0721 06/26/21 1325 06/27/21 0008 06/27/21 0631 WBC 6.1 6.0 6.9 6.4 HGB 7.1* 6.8* 8.3* 8.0* HCT 22.2* 20.5* 24.8* 23.6* PLT 96* 87* 99* 98* MCV 87.1 84.4 83.2 81.7 RDW 22.6* 22.5* 20.4* 20.8* Recent Labs 06/25/21 0825 06/26/21 0721 06/27/21 0631 NA 139 139 137 K 3.2* 3.5 3.4* CL 108* 108* 109* CO2 22* 21* 20* BUN 16 19 24* CREATININE 0.5* 0.5* 0.5* Recent Labs 06/25/21 0825 06/26/21 0721 06/27/21 0631 GLU 116* 145* 178* Recent labs Lab Units 06/26/21 1325 06/24/21 0758 06/21/21 1242 06/18/21 0730 ALBUMIN GM/DL 2.3* 2.7* 3.5 3.6 BILIRUBIN TOTAL MG/DL 4.1* 4.8* 2.5* 0.9 BILIRUBIN DIRECT MG/DL 3.2* 3.6* 1.4* 0.3* ALK PHOS U/L 355* 314* 269* 114 ALT U/L 888* 27778 LFT # sacral and a right buttock pressure ulcer present on admission - appreciate skin clinician consult #DM Hold metformin ISS HbA1c Goal f/s 140-200 #Thyroid cancer Supportive care GI ppx: not indicated DVT ppx: <span class='highlighted'>SCDs</span> Foley: no Code status: FULL Dispo: pending clinical improvement Time spent on counseling/coordination of care: 35 minutes Patient Vitals for the past 24 hrs: BP Temp Temp src Pulse Resp SpO2 06/27/21 0758 (!) 145/89 98.2 °F (36.8 °C) Oral 98 20 94 % 06/27/21 0500 (!) 141/77      06/27/21 0400 (!) 151/88 97.7 °F (36.5 °C) Oral 96 20 96 % 06/27/21 0000 (!) 143/86 97.9 °F (36.6 °C) Oral 99 20 96 % 06/26/21 2135 135/79 98.6 °F (37 °C) Oral 86 20  06/26/21 2000 140/83 98 °F (36.7 °C) Oral 114 20 95 % 06/26/21 1847 139/83 97.9 °F (36.6 °C) Oral 115 20 95 % 06/26/21 1832 127/81 97.6 °F (36.4 °C)  113 20  06/26/21 1613 134/82 97.9 °F (36.6 °C) Oral 108 20 96 % BP: (127-151)/(77-89) 145/89 Pulse: [86-115] 98 Resp: [20] 20 SpO2: [94 %-96 %] 94 % Temp: [97.6 °F (36.4 °C)-98.6 °F (37 °C)] 98.2 °F (36.8 °C) (06/26 1224-06/27 0758) Data Reviewed Recent Labs 06/26/21 0721 06/26/21 1325 06/27/21 0008 06/27/21 0631 WBC 6.1 6.0 6.9 6.4 HGB 7.1* 6.8* 8.3* 8.0* HCT 22.2* 20.5* 24.8* 23.6* PLT 96* 87* 99* 98* MCV 87.1 84.4 83.2 81.7 RDW 22.6* 22.5* 20.4* 20.8* Recent Labs 06/25/21 0825 06/26/21 0721 06/27/21 0631 NA 139 139 137 K 3.2* 3.5 3.4* CL 108* 108* 109* CO2 22* 21* 20* BUN 16 19 24* CREATININE 0.5* 0.5* 0.5* Recent Labs 06/25/21 0825 06/26/21 0721 06/27/21 0631 GLU 116* 145* 178* Recent labs Lab Units 06/26/21 1325 06/24/21 0758 06/21/21 1242 06/18/21 0730 ALBUMIN GM/DL 2.3* 2.7* 3.5 3.6 BILIRUBIN TOTAL MG/DL 4.1* 4.8* 2.5* 0.9 BILIRUBIN DIRECT MG/DL 3.2* 3.6* 1.4* 0.3* ALK PHOS U/L 355* 314* 269* 114 ALT U/L 888* 1 757* 1 857* 382* AST U/L 27779 330* 704* 1 154* 157* PROTEIN TOTAL GM/DL 3.9* 4.2* 5.2* 5.3* No results for input(s): INR in the last 72 hours.Microbiology Results (last 7 days)\"]},\"orderTimestamp\":1443715200000},{\"type\":\"notes\",\"name\":\"plan\",\"visitid\":\"ABCDEFG1234\",\"value\":\"\",\"date\":\"2021-06-28\",\"timestamp\":\"2021-06-28 00:00:00\",\"highlight\":{\"value_text_sentences\":[\"Atrophic left kidney. # sacral and a right buttock pressure ulcer present on admission - appreciate skin clinician consult #DM Hold metformin ISS HbA1c Goal f/s 140-200 #Thyroid cancer Supportive care GI ppx: not indicated DVT ppx: <span class='highlighted'>SCDs</span> Foley: no Code status: FULL Dispo: pending clinical improvement Discussed care with her oncologist at  and discussed with Urology team as well Time spent on counseling/coordination of care: 35 minutes Patient Vitals for the past 24 hrs: BP Temp Temp src Pulse Resp SpO2 Weight 06/28/21 1243       81 kg (178 lb 8 oz) 06/28/21 1200 (!) 145/84 97.6 °F (36.4 °C) Oral 92 18 97 %  06/28/21 0800 (!) 151/89 97.9 °F (36.6 °C) Oral 89 18 97 %  06/28/21 0400 127/84 97.6 °F (36.4 °C) Oral 92 18 98 %  06/28/21 0000 (!) 151/85 97.8 °F (36.6 °C) Oral 101 18 95 %  06/27/21 2000 132/79 97.6 °F (36.4 °C) Oral 102 18 95 %  06/27/21 1631 138/81 97.7 °F (36.5 °C) Oral 99 18 95 %  BP: (127-151)/(79-89) 145/84 Pulse: [89-102] 92 Resp: [18] 18 SpO2: [95 %-98 %] 97 % Temp: [97.6 °F (36.4 °C)-97.9 °F (36.6 °C)] 97.6 °F (36.4 °C) (06/27 1610-06/28 1200) Data Reviewed Recent Labs 06/27/21 0008 06/27/21 0631 06/28/21 0815 06/28/21 1017 WBC 6.9 6.4 3.9* 4.2 HGB 8.3* 8.0* 7.3* 7.8* HCT 24.8* 23.6* 22.7* 23.2* PLT 99* 98* 84* 97* MCV 83.2 81.7 87.0 83.8 RDW 20.4* 20.8* 22.0* 21.2* 27750 Recent Labs 06/26/21 0721 06/27/21 0631 06/28/21 0815 NA 139 137 138 K 3.5 3.4* 3.1* CL 108* 109* 109* CO2 21* 20* 22* BUN 19 24* 17 CREATININE 0.5* 0.5* 0.4* Recent Labs 06/26/21 0721 06/27/21 0631 06/28/21 0815 GLU 145* 178* 159* Recent labs Lab Units 06/26/21 1325 06/24/21 0758 06/21/21 1242 06/18/21 0730 ALBUMIN GM/DL 2.3* 2.7* 3.5 3.6 BILIRUBIN TOTAL MG/DL 4.1* 4.8* 2.5* 0.9 BILIRUBIN DIRECT MG/DL 3.2* 3.6* 1.4* 0.3* ALK PHOS U/L 355* 314* 269* 114 ALT U/L 888* 1 757* 1 857* 382* AST U/L 330* 704* 1 154* 157* PROTEIN TOTAL GM/DL 3.9* 4.2* 5.2* 5.3* No results for input(s): INR in the last 72 hours.Microbiology Results (last 7 days) Procedure Component Value Units Date/Time SARS-COV2 (COVID 19) BY NAAT [1252273447] (Normal) Collected: 06/26/21 1523 Lab Status: Final result Specimen: Swab from Nasopharyngeal Updated: 06/26/21 1610 SARS-CoV-2 (COVID 19) by NAAT Negative Imaging: Imaging results: Procedure Component Value Units Date/Time US abdomen - complete [1252860133] Collected: 06/28/21 1502 Order Status: Completed Updated: 06/28/21 1509 Narrative: History: Abnormal LFTs.\"]},\"orderTimestamp\":1443801600000},{\"type\":\"notes\",\"name\":\"plan\",\"visitid\":\"ABCDEFG1234\",\"value\":\"\",\"date\":\"2021-06-29\",\"timestamp\":\"2021-06-29 00:00:00\",\"highlight\":{\"value_text_sentences\":[\"Atrophic left kidney. #Sacral and a right buttock pressure ulcer present on admission Appreciate skin clinician consult #DM Hold metformin ISS HbA1c Goal f/s 140-200 #Thyroid cancer Supportive care GI ppx: not indicated DVT ppx: <span class='highlighted'>SCDs</span> : no Code status: FULL Dispo: pending clinical improvement urology recs Time spent on counseling/coordination of care: 35 minutes 06/29/2021 11:47 AM 75471 Urology PA PROGRESS NOTE S:\",\"Urology was recalled as after discussion between medical providers patient was deemed high risk but not absolutely contraindicated for necessary cystoscopy procedure. - V: Reviewed afebrile no tachycardia O2 WNL - Labs: reviewed acute anemia likely blood loss anemia with thrombocytopenia now also with acute leukopenia unclear if related to malignancy or possible developing sepsis - As above plan for OR tomorrow for cystoscopy given persistent hematuria - Recommend continue to monitor H/H and transfuse PRN - Continue adequate pain control - Encourage Incentive Spirometry use OOB and ambulating - DVT ppx: <span class='highlighted'>SCDs</span> therapeutic heparin drip please hold 5-6hrs preoperatively - Please have patient NPO after midnight for proposed procedure - Continue medical management and optimization as well as clearance for proposed procedure Discussed with Dr. .\"]},\"orderTimestamp\":1443888000000},{\"type\":\"notes\",\"name\":\"progress_note\",\"visitid\":\"ABCDEFG1234\",\"value\":\"\",\"date\":\"2021-06-30\",\"timestamp\":\"2021-06-30 00:00:00\",\"highlight\":{\"value_text_sentences\":[\"IV Piggyback 10 100 Total Intake(mL/kg) 10 (0.1) 100 (1.2) Urine (mL/kg/hr) 3500 (1.8) Total Output 3500 Net -3490 +100 LABS WBC (K/UL) Date Value 06/30/2021 1.5 (LL) HGB (GM/DL) Date Value 06/30/2021 7.8 (L) HCT (%) Date Value 06/30/2021 23.9 (L) MCV (FL) Date Value 06/30/2021 86.0 PLT (K/UL) Date Value 06/30/2021 81 (L) NEUT (%) Date Value 06/28/2021 66.6 LYMPHS (%) Date Value 06/28/2021 25.5 Lab Results Component Value Date GLU 153 (H) 06/30/2021 CALCIUM 7.0 (L) 06/30/2021 NA 138 06/30/2021 K 3.9 06/30/2021 CO2 26 06/30/2021 CL 106 06/30/2021 BUN 18 06/30/2021 CREATININE 0.4 (L) 06/30/2021 PHYSICAL EXAM GEN: Awake alert resting comfortably in bed in NAD HEENT: NC/AT RESP: No apparent respiratory distress no wheezing or cough noted ABD: Non-distended soft NTTP no rebound/rigidity/guarding GU: No gross bleeding noted MEDS Current Facility-Administered Medications:  atovaquone 150 mg/mL oral suspension 1 500 mg 1 500 mg oral Q24AD  1 500 mg at 06/29/21 1837  dextrose 50 % intravenous solution 50 mL 50 mL intravenous Q15 min PRN   glucagon (human recombinant) 1 mg injection 1 mg 1 mg intramuscular Q15 min PRN   heparin (for IV bolus) 5 000 unit/mL injection 3 250 unit 40 units/kg/DOSE intravenous Q6H PRN **AND** heparin (for IV bolus) 5 000 unit/mL 27507 injection 6 500 unit 80 units/kg/DOSE intravenous Q6H PRN   heparin 25 000 unit/250 mL in D5W infusion 2-24 units/kg/hr intravenous continuous  Held at 06/30/21 0500  hydrocortisone (PF) injection 100 mg/2 mL 75 mg 75 mg intravenous Q12H  75 mg at 06/30/21 1035  insulin lispro (HumaLOG) injection (rapid-acting) 0-4 unit 0-4 unit subcutaneous nightly   insulin lispro (HumaLOG) injection (rapid-acting) 0-6 unit 0-6 unit subcutaneous TID w/meals  1 unit at 06/28/21 1640  levETIRAcetam tablet 500 mg 500 mg oral BID  500 mg at 06/30/21 1035  levothyroxine tablet 137 MCG 137 MCG oral every other day  137 MCG at 06/29/21 0617  levothyroxine tablet 150 MCG 150 MCG oral every other day  150 MCG at 06/30/21 0640  nystatin 100 000 unit/gram cream topical TID PRN ny Kim DNP  ondansetron (PF) 2 mg/mL injection 4 mg 4 mg intravenous Q8H PRN  4 mg at 06/30/21 1248 who is POD#0 s/p cystoscopy clot evacuation and fulguration and is progressing appropriately post operatively - V: Reviewed afebrile normotensive no tachycardia O2 WNL - Labs: preoperative labs reviewed leukopenia stable anemia no post operative labs available at time of review - Continue adequate pain control - Encourage Incentive Spirometry use OOB and ambulating - DVT ppx: <span class='highlighted'>SCDs</span> Hep drip - Patient is TOV post operatively Discussed with Dr. .\"]},\"orderTimestamp\":1443974400000},{\"type\":\"notes\",\"name\":\"plan\",\"visitid\":\"ABCDEFG1234\",\"value\":\"\",\"date\":\"2021-06-30\",\"timestamp\":\"2021-06-30 00:00:00\",\"highlight\":{\"value_text_sentences\":[\"Anesthesia type: MAC Mental status (LOC assessment): Cognitive Cognitive/Neuro/Behavioral WDL: WDL arousability level of consciousness mood/behavior orientation speech (06/30/21 1337) Level of Consciousness: alert (06/30/21 1337) Arousal Level: opens eyes spontaneously arouses to voice (06/30/21 1337) Orientation: situation place (06/30/21 1337) Speech: clear (06/30/21 1337) Mood/Behavior: cooperative calm (06/30/21 1337) Additional Documentation: CAM (Confusion Assessment Method) (Group) (06/29/21 2300) Vitals Vital Signs Row Name 06/29/21 1600 06/30/21 0000 06/30/21 0900 Vital Signs Pulse 98 98 103 BP 142/89 150/84 143/89 Resp 18 18 18 Temp 97.5 °F (36.4 °C) 97.8 °F (36.6 °C) 98 °F (36.7 °C) SpO2 97 % 97 % 95 % Row Name 06/30/21 1325 06/30/21 1330 06/30/21 1340 Vital Signs Pulse 107 101 95 BP 121/73 122/80 137/86 Resp 14 16 16 Temp 97.9 °F (36.6 °C)   SpO2 93 % 98 % 98 % Row Name 06/30/21 129884 1355 Vital Signs Pulse 98 BP 141/85 Resp 18 Temp 98.1 °F (36.7 °C) SpO2 96 % Oxygen Therapy: Device (Oxygen Therapy): room air (06/30/21 1355) O2 Flow Rate (L/min): 2 L/min (06/30/21 1340) Vent Settings: Pain Assessment Preferred Pain Scale: number (Numeric Rating Pain Scale) (06/29/21 2020) Pain Side/Orientation: generalized (06/28/21 1752) Pain Location: back (06/28/21 1752) I & O: No intake/output data recorded. LDAs/Implants Lines with Linked Medications Peripheral IV (Adult) 06/27/21 Left Forearm Order Name Port Current Infusion Rate [MAR Hold] heparin 25 000 unit/250 mL in D5W infusion Start: 06/28/21 0955 potassium chloride 10 mEq in 100 mL (ISO-OSMOTIC) IVPB 100 mL/hr Start: 06/29/21 1200 [MAR Hold] hydrocortisone (PF) injection 100 mg/2 mL 75 mg Start: 06/29/21 2200 Peripheral IV (Adult) 06/29/21 Left Forearm ** No Currently Infusing Medications ** Patient Lines/Drains/Airways Status Active Central Venous Catheter Line / Line / Peripherally Inserted Central Catheter Line / Peripheral Intravenous Line / Drain / Airway / Intraosseous Line / Epidural Line / Arterial Line / Wound / Pressure Ulcer / Nasogastric/Orogastric Tube / Hemodialysis Catheter / Umbilical Venous Catheter / Foley Catheter / Intrauterine Pressure Catheter Name Placement date Placement time Site Days Peripheral IV (Adult) 06/27/21 Left Forearm 06/27/21 0610 Forearm 3 Peripheral IV (Adult) 06/29/21 Left Forearm 06/29/21  Forearm 1 Rash 06/22/21 0008 other (see comments) midline perineum other (see comments) 06/22/21 0008 8 Wound (Adult Obstetrics Pediatric)- NOT for mucosal pressure injury 06/21/21 2000 other (see comments) midline sacral spine pressure injury 06/21/21 2000 8 Wound (Adult Obstetrics Pediatric)- NOT for mucosal pressure injury 06/21/21 2000 Right 129885 posterior buttocks pressure injury 06/21/21 2000 8 Incision 06/30/21 urethral meatus 06/30/21 1306 less than 1 Estimated Blood Loss: Sequential Compression Device (<span class='highlighted'>SCDs</span>) on/off: VTE Prevention/Management: other (see comments) (pt is on heparin gtt scd held MD  aware) (06/29/21 0944) Treatment Administered: levETIRAcetam tablet 500 mg ( oral Dose Auto Held 07/6/21 2100) insulin lispro (HumaLOG) injection (rapid-acting) 0-6 unit ( subcutaneous Dose Auto Held 07/6/21 1700) insulin lispro (HumaLOG) injection (rapid-acting) 0-4 unit ( subcutaneous Dose Auto Held 07/6/21 2200) dextrose 50 % intravenous solution 50 mL ( intravenous MAR Hold 06/30/21 1134) glucagon (human recombinant) 1 mg injection 1 mg ( intramuscular MAR Hold 06/30/21 1134) nystatin 100 000 unit/gram cream ( topical MAR Hold 06/30/21 1134) atovaquone 150 mg/mL oral suspension 1 500 mg ( oral Dose Auto Held 07/7/21 1800) levothyroxine tablet 137 MCG ( oral Dose Auto Held 07/7/21 0600) levothyroxine tablet 150 MCG ( oral Dose Auto Held 07/8/21 0600) ondansetron (PF) 2 mg/mL injection 4 mg (4 mg intravenous Given 06/30/21 1248) heparin 25 000 unit/250 mL in D5W infusion ( intravenous MAR Hold 06/30/21 1134) heparin (for IV bolus) 5 000 unit/mL injection 3 250 unit ( intravenous MAR Hold 06/30/21 1134) And heparin (for IV bolus) 5 000 unit/mL injection 6 500 unit ( intravenous MAR Hold 06/30/21 1134) hydrocortisone (PF) injection 100 mg/2 mL 75 mg ( intravenous Dose Auto Held 07/9/21 2200) meropenem 500 mg in sterile water for injection 10 mL IV Push (has no administration in time range) fentaNYL (PF) 50 mcg/mL injection 25 MCG (has no administration in time range) fentaNYL (PF) 50 mcg/mL injection 50 MCG (has no administration in time range) ondansetron (PF) 2 mg/mL injection 4 mg (has no administration in time range) prochlorperazine 5 mg/mL injection 5 mg (has no 129886 administration in time range) sodium chloride 0.9 % bolus 1 000 mL (0 mL intravenous Stopped 06/21/21 1318) sodium chloride 0.9 % bolus 1 000 mL (0 mL intravenous Stopped 06/21/21 1313) acetaminophen tablet 975 mg (975 mg oral Given 06/21/21 1406) meropenem 500 mg in sterile water for injection 10 mL IV Push (500 mg intravenous Given 06/21/21 1407) vancomycin 1 000 mg in dextrose 5 % 250 mL IVPB-MBP (1 000 mg intravenous Given 06/21/21 1407) iohexoL 350 mg iodine/mL injection 100 mL (100 mL intravenous Given 06/21/21 1355) sodium chloride 0.9 % bolus 1 000 mL (0 mL intravenous Stopped 06/21/21 1553) vancomycin 1 000 mg in dextrose 5 % 250 mL IVPB-MBP (1 000 mg intravenous Given 06/21/21 2240) meropenem 500 mg in sterile water for injection 10 mL IV Push (500 mg intravenous Given 06/21/21 2115) meropenem 500 mg in sterile water for injection 10 mL IV Push (500 mg intravenous Given 06/29/21 1238) potassium chloride 10 mEq in 100 mL (ISO-OSMOTIC) IVPB (10 mEq intravenous Given 06/22/21 2219) potassium chloride 10 mEq in 100 mL (ISO-OSMOTIC) IVPB (10 mEq intravenous Given 06/23/21 2236) potassium chloride ER tablet 20 mEq (20 mEq oral Given 06/24/21 0611) potassium chloride ER tablet 20 mEq (20 mEq oral Given 06/25/21 0808) potassium chloride ER tablet 20 mEq (20 mEq oral Given 06/30/21 0028) potassium chloride 10 mEq in 100 mL (ISO-OSMOTIC) IVPB (10 mEq intravenous Given 06/29/21 1716) Blood Transfusion Record Product Unit Status Volume Start End Transfuse RBC:Transfusion Rate: As fast as possible W2004 21 398456 V-E0332V00 Completed 06/26/21 2317 06/26/21 1832 06/26/21 2135 Additional Documentation: I  RN gave report to  RN on 06/30/2021 1:59 PM 27218  Hospital - Hospitalist Department DAILY MEDICINE PROGRESS NOTE The patient's medical records have been reviewed.Admit Date: 06/21/2021 Subjective: Translator Used: lung cancer stage IV with mets to the brain and liver recently diagnosed with bilateral PE on therapeutic lovenox admitted for sepsis POA secondary to UTI.\",\"Atrophic left kidney. #Sacral and a right buttock pressure ulcer present on admission Appreciate skin clinician consult #DM Hold metformin ISS HbA1c Goal f/s 140-200 #Thyroid cancer Supportive care GI ppx: not indicated DVT ppx: <span class='highlighted'>SCDs</span> Foley: no Code status: FULL Dispo: pending clinical improvement urology recs AC Time spent on counseling/coordination of care: 35 minutes  06/30/2021 3:16 PM 27710 Holistic Nursing Note Referred by NP for pain management.Referral stated that this patient \\\"does not like to be touched\\\" but was requesting aromatherapy or Healing Touch.\"]},\"orderTimestamp\":1443974400000},{\"type\":\"notes\",\"name\":\"plan\",\"visitid\":\"ABCDEFG1234\",\"value\":\"\",\"date\":\"2021-07-01\",\"timestamp\":\"2021-07-01 00:00:00\",\"highlight\":{\"value_text_sentences\":[\"VITALS BP: (121-141)/(72-86) 128/85 Pulse: [94-110] 95 Resp: [14-18] 18 SpO2: [93 %-98 %] 96 % Temp: [97.6 °F (36.4 °C)-98.2 °F (36.8 °C)] 98 °F (36.7 °C) (06/30 1012-07/01 0748) I&O I/O Report 06/29 0700 - 06/30 0659 06/30 0700 - 07/01 0659 07/01 0700 - 07/02 0659 IV Piggyback 100 Total Intake(mL/kg) 100 (1.2) Urine (mL/kg/hr) Total Output Net +100 Unmeasured Stool Occurrence 1 x LABS WBC (K/UL) Date Value 07/01/2021 0.8 (LL) HGB (GM/DL) Date Value 07/01/2021 7.8 (L) HCT (%) Date Value 07/01/2021 25.2 (L) MCV (FL) Date Value 07/01/2021 90.3 PLT (K/UL) Date Value 07/01/2021 90 (L) NEUT (%) Date Value 06/28/2021 66.6 LYMPHS (%) Date Value 06/28/2021 25.5 Lab Results Component Value Date GLU 147 (H) 07/01/2021 CALCIUM 7.0 (L) 07/01/2021 NA 139 07/01/2021 K 3.6 07/01/2021 CO2 27 07/01/2021 CL 106 07/01/2021 BUN 18 07/01/2021 CREATININE 0.4 (L) 07/01/2021 PHYSICAL EXAM GEN: Awake alert resting comfortably in bed in NAD HEENT: NC/AT RESP: No apparent respiratory distress no wheezing or cough noted ABD: Non-distended soft NTTP no rebound/rigidity/guarding GU: No gross bleeding noted MEDS Current Facility-Administered Medications:  atovaquone 150 mg/mL oral suspension 1 500 mg 1 500 mg oral Q24AD  1 500 mg at 06/30/21 1845  dextrose 50 % intravenous solution 50 mL 50 mL intravenous Q15 min PRN   glucagon (human recombinant) 1 mg injection 1 mg 1 mg intramuscular Q15 min PRN   heparin (for IV bolus) 5 000 unit/mL injection 3 250 unit 40 units/kg/DOSE intravenous Q6H 27231 PRN 3 250 unit at 07/01/21 0115 **AND** heparin (for IV bolus) 5 000 unit/mL injection 6 500 unit 80 units/kg/DOSE intravenous Q6H PRN   heparin 25 000 unit/250 mL in D5W infusion 2-24 units/kg/hr intravenous continuous  Last Rate: 5.7 mL/hr at 07/01/21 0950 7 units/kg/hr at 07/01/21 0950  hydrocortisone (PF) injection 100 mg/2 mL 75 mg 75 mg intravenous Q12H  75 mg at 07/01/21 0854  insulin lispro (HumaLOG) injection (rapid-acting) 0-4 unit 0-4 unit subcutaneous nightly   insulin lispro (HumaLOG) injection (rapid-acting) 0-6 unit 0-6 unit subcutaneous TID w/meals  1 unit at 06/28/21 1640  levETIRAcetam tablet 500 mg 500 mg oral BID  500 mg at 07/01/21 0854  levothyroxine tablet 137 MCG 137 MCG oral every other day  137 MCG at 07/01/21 0653  levothyroxine tablet 150 MCG 150 MCG oral every other day  150 MCG at 06/30/21 0640  nystatin 100 000 unit/gram cream topical TID PRN ny Kim DNP  ondansetron (PF) 2 mg/mL injection 4 mg 4 mg intravenous Q8H PRN  4 mg at 06/30/21 1248 ASSESSMENT/PLAN who is POD#1 s/p cystoscopy clot evacuation and fulguration and is progressing appropriately post operatively - V: Reviewed afebrile normotensive no tachycardia O2 WNL - Labs: persistent leukopenia possibly 2/2 malignancy otherwise WNL - Patient reportedly voiding clear yellow urine without difficulty - No further acute Urologic intervention indicated at this time - Continue adequate pain control - Encourage Incentive Spirometry use OOB and ambulating - DVT ppx: <span class='highlighted'>SCDs</span> Hep drip - Remainder of care per medical team - Please re-consult as needed Discussed with Dr. 27711 Physical Therapy Progress Note Patient Name: \",\"Atrophic left kidney. #Sacral and a right buttock pressure ulcer present on admission Appreciate skin 27840 clinician consult #DM Hold metformin ISS HbA1c Goal f/s 140-200 #Thyroid cancer Supportive care GI ppx: not indicated DVT ppx: <span class='highlighted'>SCDs</span> and hep drip to eliquis Foley: no Code status: FULL Dispo: pending clinical improvement urology recs AC Time spent on counseling/coordination of care: > 35 minutes 27805 Holistic Nursing Note Follow-up visit to see patient at bedside.\"]},\"orderTimestamp\":1444060800000}]]},{\"type\":\"single\",\"hide\":false,\"triggeredAt\":[],\"details\":[[{\"type\":\"notes\",\"name\":\"plan\",\"visitid\":\"ABCDEFG1234\",\"value\":\"\",\"date\":\"2021-06-26\",\"timestamp\":\"2021-06-26 00:00:00\",\"highlight\":{\"value_text_sentences\":[\"Will initiate CBI for now and monitor progression of hematuria. - V: Reviewed afebrile tachycardic O2 WNL - Labs: reviewed 27533 acute anemia likely blood loss anemia with <span class='highlighted'>thrombocytopenia</span> otherwise WNL - As above will plan to initiate CBI and monitor hematuria for now as patient is high risk candidate for surgical intervention at this time - Recommend continue to monitor H/H and transfuse PRN - Continue adequate pain control - Encourage Incentive Spirometry use OOB and ambulating - DVT ppx: SCDs AC held for anemia and hematuria Discussed with Dr. endorsed to Dr.\"]},\"orderTimestamp\":1443628800000},{\"type\":\"notes\",\"name\":\"plan\",\"visitid\":\"ABCDEFG1234\",\"value\":\"\",\"date\":\"2021-06-29\",\"timestamp\":\"2021-06-29 00:00:00\",\"highlight\":{\"value_text_sentences\":[\"Urology was recalled as after discussion between medical providers patient was deemed high risk but not absolutely contraindicated for necessary cystoscopy procedure. - V: Reviewed afebrile no tachycardia O2 WNL - Labs: reviewed acute anemia likely blood loss anemia with <span class='highlighted'>thrombocytopenia</span> now also with acute leukopenia unclear if related to malignancy or possible developing sepsis - As above plan for OR tomorrow for cystoscopy given persistent hematuria - Recommend continue to monitor H/H and transfuse PRN - Continue adequate pain control - Encourage Incentive Spirometry use OOB and ambulating - DVT ppx: SCDs therapeutic heparin drip please hold 5-6hrs preoperatively - Please have patient NPO after midnight for proposed procedure - Continue medical management and optimization as well as clearance for proposed procedure Discussed with Dr. .\"]},\"orderTimestamp\":1443888000000},{\"type\":\"notes\",\"name\":\"rrt_code\",\"visitid\":\"ABCDEFG1234\",\"value\":\"\",\"date\":\"2021-07-04\",\"timestamp\":\"2021-07-04 00:00:00\",\"highlight\":{\"value_text_sentences\":[\"No signs of bleeding at this time. # New Afib with RVR and NSVT - already on AC with eliquis - on amiodarone per Dr. recommendations during RRT 07/4/21 early morning - ECHO ordered # elevated troponin due to NSVT and Afib+RVR as above - EKG reviewed - echo pending - patient already on AC and represent poor candidate for cardiac catheterization/antiplatelets given her pancypenia/<span class='highlighted'>thrombocytopenia</span> And metastatic cancer - will follow cards input #Acute hypoxemic resp failure due to lung cancer #Metastatic lung cancer to brain and liver per Hx Supportive care Received chemo x1 was to resume this month but LFTs elevated Follows at  palliative care on board #Acute liver injury / Abnormal LFT and jaundice probably due to chemo Trend LFT-->improving since 27563 admission Abdomen US: Fatty liver.No evidence of cholelithiasis within the limitations of examination.\"]},\"orderTimestamp\":1444320000000},{\"type\":\"notes\",\"name\":\"plan\",\"visitid\":\"ABCDEFG1234\",\"value\":\"\",\"date\":\"2021-07-05\",\"timestamp\":\"2021-07-05 00:00:00\",\"highlight\":{\"value_text_sentences\":[\"No signs of bleeding at this time. # New Afib with RVR and NSVT - already on AC with eliquis - on amiodarone per Dr. recommendations during RRT 07/4/21 early morning - ECHO ordered # elevated troponin due to NSVT and Afib+RVR as above - EKG reviewed - echo pending - patient already on AC and represent poor candidate for cardiac catheterization/antiplatelets given her pancypenia/<span class='highlighted'>thrombocytopenia</span> recent hematuria and patient is already on Eliquis.And metastatic cancer - HR much improved on Amiodarone now #Acute hypoxemic resp failure due to lung cancer #Metastatic lung cancer to brain and liver per Hx Supportive care Received chemo x1 was to resume this month but LFTs elevated Follows at  palliative care on board #Acute liver injury / Abnormal LFT and jaundice probably due to chemo Trend LFT-->improving since admission Abdomen US: Fatty liver.\"]},\"orderTimestamp\":1444406400000}]]},{\"type\":\"single\",\"hide\":false,\"triggeredAt\":[],\"details\":[[{\"type\":\"diagnosis\",\"name\":\"D61810\",\"visitid\":\"ABCDEFG1234\",\"value\":\"7\",\"date\":\"2021-07-08\",\"timestamp\":\"2021-07-08 00:00:00\",\"value_text_sentences\":[\"Yes\"],\"orderTimestamp\":1444665600000}]]},{\"type\":\"single\",\"hide\":false,\"triggeredAt\":[],\"details\":[[{\"type\":\"notes\",\"name\":\"plan\",\"visitid\":\"ABCDEFG1234\",\"value\":\"\",\"date\":\"2021-06-24\",\"timestamp\":\"2021-06-24 00:00:00\",\"highlight\":{\"value_text_sentences\":[\"AC has since been held. Recommend continue to <span class='highlighted'>hold</span> <span class='highlighted'>AC</span> until resolution of hematuria and monitor patient at least 24hrs after AC restarted for any recurrence of hematuria.No indication for acute Urologic intervention at this time.\"]},\"orderTimestamp\":1443456000000}]]},{\"type\":\"single\",\"hide\":false,\"triggeredAt\":[],\"details\":[[{\"type\":\"notes\",\"name\":\"plan\",\"visitid\":\"ABCDEFG1234\",\"value\":\"\",\"date\":\"2021-06-30\",\"timestamp\":\"2021-06-30 00:00:00\",\"highlight\":{\"value_text_sentences\":[\"Anesthesia type: MAC Mental status (LOC assessment): Cognitive Cognitive/Neuro/Behavioral WDL: WDL arousability level of consciousness mood/behavior orientation speech (06/30/21 1337) Level of Consciousness: alert (06/30/21 1337) Arousal Level: opens eyes spontaneously arouses to voice (06/30/21 1337) Orientation: situation place (06/30/21 1337) Speech: clear (06/30/21 1337) Mood/Behavior: cooperative calm (06/30/21 1337) Additional Documentation: CAM (Confusion Assessment Method) (Group) (06/29/21 2300) Vitals Vital Signs Row Name 06/29/21 1600 06/30/21 0000 06/30/21 0900 Vital Signs Pulse 98 98 103 BP 142/89 150/84 143/89 Resp 18 18 18 Temp 97.5 °F (36.4 °C) 97.8 °F (36.6 °C) 98 °F (36.7 °C) SpO2 97 % 97 % 95 % Row Name 06/30/21 1325 06/30/21 1330 06/30/21 1340 Vital Signs Pulse 107 101 95 BP 121/73 122/80 137/86 Resp 14 16 16 Temp 97.9 °F (36.6 °C)   SpO2 93 % 98 % 98 % Row Name 06/30/21 129884 1355 Vital Signs Pulse 98 BP 141/85 Resp 18 Temp 98.1 °F (36.7 °C) SpO2 96 % Oxygen Therapy: Device (Oxygen Therapy): room air (06/30/21 1355) O2 Flow Rate (L/min): 2 L/min (06/30/21 1340) Vent Settings: Pain Assessment Preferred Pain Scale: number (Numeric Rating Pain Scale) (06/29/21 2020) Pain Side/Orientation: generalized (06/28/21 1752) Pain Location: back (06/28/21 1752) I & O: No intake/output data recorded. LDAs/Implants Lines with Linked Medications Peripheral IV (Adult) 06/27/21 Left Forearm Order Name Port Current Infusion Rate [MAR <span class='highlighted'>Hold</span>] <span class='highlighted'>heparin</span> 25 000 unit/250 mL in D5W infusion Start: 06/28/21 0955 potassium chloride 10 mEq in 100 mL (ISO-OSMOTIC) IVPB 100 mL/hr Start: 06/29/21 1200 [MAR Hold] hydrocortisone (PF) injection 100 mg/2 mL 75 mg Start: 06/29/21 2200 Peripheral IV (Adult) 06/29/21 Left Forearm ** No Currently Infusing Medications ** Patient Lines/Drains/Airways Status Active Central Venous Catheter Line / Line / Peripherally Inserted Central Catheter Line / Peripheral Intravenous Line / Drain / Airway / Intraosseous Line / Epidural Line / Arterial Line / Wound / Pressure Ulcer / Nasogastric/Orogastric Tube / Hemodialysis Catheter / Umbilical Venous Catheter / Foley Catheter / Intrauterine Pressure Catheter Name Placement date Placement time Site Days Peripheral IV (Adult) 06/27/21 Left Forearm 06/27/21 0610 Forearm 3 Peripheral IV (Adult) 06/29/21 Left Forearm 06/29/21  Forearm 1 Rash 06/22/21 0008 other (see comments) midline perineum other (see comments) 06/22/21 0008 8 Wound (Adult Obstetrics Pediatric)- NOT for mucosal pressure injury 06/21/21 2000 other (see comments) midline sacral spine pressure injury 06/21/21 2000 8 Wound (Adult Obstetrics Pediatric)- NOT for mucosal pressure injury 06/21/21 2000 Right 129885 posterior buttocks pressure injury 06/21/21 2000 8 Incision 06/30/21 urethral meatus 06/30/21 1306 less than 1 Estimated Blood Loss: Sequential Compression Device (SCDs) on/off: VTE Prevention/Management: other (see comments) (pt is on heparin gtt scd held MD  aware) (06/29/21 0944) Treatment Administered: levETIRAcetam tablet 500 mg ( oral Dose Auto Held 07/6/21 2100) insulin lispro (HumaLOG) injection (rapid-acting) 0-6 unit ( subcutaneous Dose Auto Held 07/6/21 1700) insulin lispro (HumaLOG) injection (rapid-acting) 0-4 unit ( subcutaneous Dose Auto Held 07/6/21 2200) dextrose 50 % intravenous solution 50 mL ( intravenous MAR Hold 06/30/21 1134) glucagon (human recombinant) 1 mg injection 1 mg ( intramuscular MAR Hold 06/30/21 1134) nystatin 100 000 unit/gram cream ( topical MAR Hold 06/30/21 1134) atovaquone 150 mg/mL oral suspension 1 500 mg ( oral Dose Auto Held 07/7/21 1800) levothyroxine tablet 137 MCG ( oral Dose Auto Held 07/7/21 0600) levothyroxine tablet 150 MCG ( oral Dose Auto Held 07/8/21 0600) ondansetron (PF) 2 mg/mL injection 4 mg (4 mg intravenous Given 06/30/21 1248) heparin 25 000 unit/250 mL in D5W infusion ( intravenous MAR Hold 06/30/21 1134) heparin (for IV bolus) 5 000 unit/mL injection 3 250 unit ( intravenous MAR Hold 06/30/21 1134) And heparin (for IV bolus) 5 000 unit/mL injection 6 500 unit ( intravenous MAR Hold 06/30/21 1134) hydrocortisone (PF) injection 100 mg/2 mL 75 mg ( intravenous Dose Auto Held 07/9/21 2200) meropenem 500 mg in sterile water for injection 10 mL IV Push (has no administration in time range) fentaNYL (PF) 50 mcg/mL injection 25 MCG (has no administration in time range) fentaNYL (PF) 50 mcg/mL injection 50 MCG (has no administration in time range) ondansetron (PF) 2 mg/mL injection 4 mg (has no administration in time range) prochlorperazine 5 mg/mL injection 5 mg (has no 129886 administration in time range) sodium chloride 0.9 % bolus 1 000 mL (0 mL intravenous Stopped 06/21/21 1318) sodium chloride 0.9 % bolus 1 000 mL (0 mL intravenous Stopped 06/21/21 1313) acetaminophen tablet 975 mg (975 mg oral Given 06/21/21 1406) meropenem 500 mg in sterile water for injection 10 mL IV Push (500 mg intravenous Given 06/21/21 1407) vancomycin 1 000 mg in dextrose 5 % 250 mL IVPB-MBP (1 000 mg intravenous Given 06/21/21 1407) iohexoL 350 mg iodine/mL injection 100 mL (100 mL intravenous Given 06/21/21 1355) sodium chloride 0.9 % bolus 1 000 mL (0 mL intravenous Stopped 06/21/21 1553) vancomycin 1 000 mg in dextrose 5 % 250 mL IVPB-MBP (1 000 mg intravenous Given 06/21/21 2240) meropenem 500 mg in sterile water for injection 10 mL IV Push (500 mg intravenous Given 06/21/21 2115) meropenem 500 mg in sterile water for injection 10 mL IV Push (500 mg intravenous Given 06/29/21 1238) potassium chloride 10 mEq in 100 mL (ISO-OSMOTIC) IVPB (10 mEq intravenous Given 06/22/21 2219) potassium chloride 10 mEq in 100 mL (ISO-OSMOTIC) IVPB (10 mEq intravenous Given 06/23/21 2236) potassium chloride ER tablet 20 mEq (20 mEq oral Given 06/24/21 0611) potassium chloride ER tablet 20 mEq (20 mEq oral Given 06/25/21 0808) potassium chloride ER tablet 20 mEq (20 mEq oral Given 06/30/21 0028) potassium chloride 10 mEq in 100 mL (ISO-OSMOTIC) IVPB (10 mEq intravenous Given 06/29/21 1716) Blood Transfusion Record Product Unit Status Volume Start End Transfuse RBC:Transfusion Rate: As fast as possible W2004 21 398456 V-E0332V00 Completed 06/26/21 2317 06/26/21 1832 06/26/21 2135 Additional Documentation: I  RN gave report to  RN on 06/30/2021 1:59 PM 27218  Hospital - Hospitalist Department DAILY MEDICINE PROGRESS NOTE The patient's medical records have been reviewed.Admit Date: 06/21/2021 Subjective: lung cancer stage IV with mets to the brain and liver recently diagnosed with bilateral PE on therapeutic lovenox admitted for sepsis POA secondary to UTI.\",\"Atrophic left kidney. Medications Scheduled [MAR Hold] atovaquone 1 500 mg oral Q24AD [MAR Hold] hydrocortisone sodium succinate 75 mg intravenous Q12H [MAR Hold] insulin lispro (HumaLOG) 0-4 unit subcutaneous nightly [MAR Hold] insulin lispro (HumaLOG) 0-6 unit subcutaneous TID w/meals [MAR Hold] levETIRAcetam 500 mg oral BID [MAR Hold] levothyroxine 137 MCG oral every other day [MAR Hold] levothyroxine 150 MCG oral every other day Infusions [MAR <span class='highlighted'>Hold</span>] <span class='highlighted'>heparin</span> 2-24 units/kg/hr Last Rate: Stopped (06/30/21 0500) PRN [MAR Hold] dextrose 50 mL intravenous Q15 min PRN [MAR Hold] glucagon (human recombinant) 1 mg intramuscular Q15 min PRN [MAR <span class='highlighted'>Hold</span>] <span class='highlighted'>heparin</span> (for IV bolus) 40 units/kg/DOSE intravenous Q6H PRN And [MAR <span class='highlighted'>Hold</span>] <span class='highlighted'>heparin</span> (for IV bolus) 80 units/kg/DOSE intravenous Q6H PRN [MAR Hold] nystatin topical TID PRN [MAR Hold] ondansetron 4 mg intravenous Q8H PRN Hospital Course by Problem Hospital Severe sepsis (Chronic) * (Principal) Urinary tract infection Relevant Orders Case Request: CYSTOSCOPY (Completed) Tissue AFB Culture AFB CULTURE AND SMEAR Assessment & Plan: lung cancer stage IV with mets to the brain and liver recently diagnosed with bilateral 27228 PE on therapeutic lovenox admitted for sepsis POA secondary to UTI.\"]},\"orderTimestamp\":1443974400000},{\"type\":\"notes\",\"name\":\"consult\",\"visitid\":\"ABCDEFG1234\",\"value\":\"\",\"date\":\"2021-07-08\",\"timestamp\":\"2021-07-08 00:00:00\",\"highlight\":{\"value_text_sentences\":[\"Patient is in normal sinus rhythm. Hematuria <span class='highlighted'>Hold</span> <span class='highlighted'>heparin</span>.If hematuria persists urology should be summoned to consult Metastatic lung cancer Received Keytruda once.\",\"Patient is in normal sinus rhythm. Hematuria <span class='highlighted'>Hold</span> <span class='highlighted'>heparin</span>.If hematuria persists urology should be summoned to consult Sepsis Blood cultures and broad spectrum IV antibiotics.\"]},\"orderTimestamp\":1444665600000}]]},{\"type\":\"single\",\"hide\":false,\"triggeredAt\":[],\"details\":[[{\"type\":\"notes\",\"name\":\"plan\",\"visitid\":\"ABCDEFG1234\",\"value\":\"\",\"date\":\"2021-06-28\",\"timestamp\":\"2021-06-28 00:00:00\",\"highlight\":{\"value_text_sentences\":[\"Dr . Dr.  to round this afternoon 27767 further <span class='highlighted'>bleeding</span> would give TOV 06/29 Urology singing off please reconsult PRN 115981 Patient declined acute rehab spoke with patient at the bedside: still acute starting a heparin drip on O2 for comfort.Plan remains for STR Dumont is looking into patient care Other referrals initiated that are on par with patient insurance.\"]},\"orderTimestamp\":1443801600000},{\"type\":\"notes\",\"name\":\"plan\",\"visitid\":\"ABCDEFG1234\",\"value\":\"\",\"date\":\"2021-06-30\",\"timestamp\":\"2021-06-30 00:00:00\",\"highlight\":{\"value_text_sentences\":[\"Urology was recalled as after discussion between medical providers patient was deemed high risk but not absolutely contraindicated for necessary cystoscopy procedure.The following portions of the patient's history were reviewed and updated as appropriate:  and Lung cancer metastatic to brain..Review of SystemsPertinent items are noted in HPI.Objective Temp: [97.5 °F (36.4 °C)-98 °F (36.7 °C)] 98 °F (36.7 °C)Pulse: [98-103] 103Resp: [18] 18BP: (142-150)/(84-89) 143/89SpO2: [95 %-97 %] 95 %I/O last 3 completed shifts:In: 100 [IV Piggyback:100]Out: - No intake/output data recorded.- Prior to the procedure procedural details risks benefits indications and alternatives were discussed at length patient asked good and pertinent questions all of which were answered to the best of my ability and the patient agreed to the procedure. - Presents for cystoscopy clot evacuation and fulguration of <span class='highlighted'>bleeding</span>- Patient expressed understanding 203956 of the plan of care and all of their questions were answered.Dr.\",\"Remarkable findings as described above. The area of <span class='highlighted'>bleeding</span> was fulgurated with excellent hemostasis.At the end of the procedure the ureteral orifices were confirmed to be patent with clear efflux bilaterally.\",\"PLAN/FOLLOW-UP: Ensure patient emptying bladder adequately recommend CIC vs placing indwelling catheter unless patient continues to retain >300cc urine. Spoke to xxx that although the foley was removed patient may require it in the future if there is recurrence of <span class='highlighted'>bleeding</span>.Specimens: ID Type Source Tests Collected by Time Destination A : CLOT AND TISSUE FROM BLADDER FOR CULTURE Tissue Soft tissue TISSUE AFB CULTURE 06/30/2021 1314 Implants: * No implants in log * Estimated Blood Loss: * No values recorded between 06/30/2021 12:59 PM and 06/30/2021 1:17 PM * Drains: Post-Procedure Information: Post-Op Diagnosis Codes: * Urinary tract infection [N39.0] Patient's condition to PACU: awakened from anesthesia extubated and taken to the recovery room in a stable condition having suffered no apparent untoward event.\",\"#Severe sepsis POA secondary to UTI resolved SIRS +2 (BP WBC) + urinary source UA noticed urine cx noted sensitive to meropenem ID recs apprreciated meropenem 06/22 - Lactic acid wnl IV fluids Tylenol 650mg q6h PRN for fever Blood cx NGTD Stress dose steroids taper 75mg q12h from 06/29 WBC improved afebrile now #Suspected hemorrhagic cystitis with acute blood loss anemia IVF Urology consulted recs appreciated s/p cystoscopy under GA 06/30 without incidence Spoke with  physician Dr.  06/29 and updated him on plan of care agrees with exploratory cystoscopy before exploring the need for an IVC filter for bilateral PE Heparin gtt after procedure and will continue x 24 hours to monitor for post op <span class='highlighted'>bleeding</span> Monitor CBC Active T&S Transfuse if Hgb <7 S/p IV abx course #Recent bilateral PE At home On therapeutic lovenox was held in setting of active gross hematuria TTE with normal LV/RV function Patient at high risk for DVT/PE given her Hx and active cancer Continue heparin drip with close monitoring once hematuria resolves can hopefully d/c on DOAC if not will need IVC filter discussed with patient`s oncologist who agrees #Acute hypoxemic resp failure improved Started feeling some SOB overnight 06/28/21 IVF stopped 06/28 CXR without any congestion and no crackles on exam.Possibility either her lung cancer vs possible recurrent PE vs other etiology patient was started on heparin gtt again as discussed above patient is being covered with antibiotics so unlikely to develop any PNA (9/22 - 06/29) Continue O2 2L NC and monitor for now #Metastatic lung cancer to brain and liver per Hx Supportive care Received chemo x1 was to resume this month but LFTs elevated Follows at  Re-check LFT- improving as below To Resume chemo after d/c once cleared by oncology palliative care on board 27229 #Acute liver injury / Abnormal LFT and jaundice probably due to chemo Trend LFT-->improving since admission Abdomen US: Fatty liver.\"]},\"orderTimestamp\":1443974400000},{\"type\":\"notes\",\"name\":\"plan\",\"visitid\":\"ABCDEFG1234\",\"value\":\"\",\"date\":\"2021-07-03\",\"timestamp\":\"2021-07-03 00:00:00\",\"highlight\":{\"value_text_sentences\":[\"Spoke with  physician Dr.  06/29 and updated him on plan of care agreed with exploratory cystoscopy before exploring the need for an IVC filter for bilateral PE Heparin gtt after procedure and will continue x 24 hours to monitor for post op <span class='highlighted'>bleeding</span> Monitor CBC Active T&S Transfuse if Hgb <7 S/p IV abx course #Recent bilateral PE At home On therapeutic lovenox was held in setting of active gross hematuria TTE with normal LV/RV function Patient at high risk for DVT/PE given her Hx and active cancer Discussed the case with Dr. from  and reported no preference as to which AC to use.\",\"Spoke with  physician Dr.  06/29 and updated him on plan of care agreed with exploratory cystoscopy before exploring the need for an IVC filter for bilateral PE Heparin gtt after procedure and will continue x 24 hours to monitor for post op <span class='highlighted'>bleeding</span> Monitor CBC Active T&S Transfuse if Hgb <7 S/p IV abx course #Recent bilateral PE At home On therapeutic lovenox was held in setting of active gross hematuria TTE with normal LV/RV function Patient at high risk for DVT/PE given her Hx and active cancer Discussed the case with Dr. from  Oncology and reported no preference as to which AC to use.\"]},\"orderTimestamp\":1444233600000}]]},{\"type\":\"single\",\"hide\":false,\"triggeredAt\":[],\"details\":[[{\"type\":\"notes\",\"name\":\"assessment\",\"visitid\":\"ABCDEFG1234\",\"value\":\"\",\"date\":\"2021-06-23\",\"timestamp\":\"2021-06-23 00:00:00\",\"highlight\":{\"value_text_sentences\":[\"Please see report for CTA of the chest performed on the same day for additional findings. Assessment and Plan lovenox for PE with stage 4 lung CA with Mets with suspected hematuria pt at this time refusing GYN examination but with dark maroon blood x2 in commode after voiding no BM in last day unlikely this is <span class='highlighted'>GIB</span> but certainly could be vaginal or could be from bladder given recent balloon and cyto in the setting on AC.Also common to have hematuria with UTI.\",\"Please see report for CTA of the chest performed on the same day for additional findings. Assessment and Plan lovenox for PE with stage 4 lung CA with Mets with suspected hematuria pt at this time refusing GYN examination but with dark maroon blood x2 in commode after voiding no BM in last day unlikely this is <span class='highlighted'>GIB</span> but certainly could be vaginal or could be from bladder given recent balloon and cyto in the setting on AC.At this time would continue to monitor HGB would not place foley as patient is voiding freely and not with retention.\"]},\"orderTimestamp\":1443369600000}]]},{\"type\":\"single\",\"hide\":false,\"triggeredAt\":[],\"details\":[[{\"type\":\"notes\",\"name\":\"plan\",\"visitid\":\"ABCDEFG1234\",\"value\":\"\",\"date\":\"2021-06-26\",\"timestamp\":\"2021-06-26 00:00:00\",\"highlight\":{\"value_text_sentences\":[\"Will initiate CBI for now and monitor progression of hematuria. - V: Reviewed afebrile tachycardic O2 WNL - Labs: reviewed 27533 acute anemia likely blood loss anemia with <span class='highlighted'>thrombocytopenia</span> otherwise WNL - As above will plan to initiate CBI and monitor hematuria for now as patient is high risk candidate for surgical intervention at this time - Recommend continue to monitor H/H and transfuse PRN - Continue adequate pain control - Encourage Incentive Spirometry use OOB and ambulating - DVT ppx: SCDs AC held for anemia and hematuria Discussed with Dr. endorsed to Dr.\"]},\"orderTimestamp\":1443628800000},{\"type\":\"notes\",\"name\":\"plan\",\"visitid\":\"ABCDEFG1234\",\"value\":\"\",\"date\":\"2021-06-29\",\"timestamp\":\"2021-06-29 00:00:00\",\"highlight\":{\"value_text_sentences\":[\"Urology was recalled as after discussion between medical providers patient was deemed high risk but not absolutely contraindicated for necessary cystoscopy procedure. - V: Reviewed afebrile no tachycardia O2 WNL - Labs: reviewed acute anemia likely blood loss anemia with <span class='highlighted'>thrombocytopenia</span> now also with acute leukopenia unclear if related to malignancy or possible developing sepsis - As above plan for OR tomorrow for cystoscopy given persistent hematuria - Recommend continue to monitor H/H and transfuse PRN - Continue adequate pain control - Encourage Incentive Spirometry use OOB and ambulating - DVT ppx: SCDs therapeutic heparin drip please hold 5-6hrs preoperatively - Please have patient NPO after midnight for proposed procedure - Continue medical management and optimization as well as clearance for proposed procedure Discussed with Dr. .\"]},\"orderTimestamp\":1443888000000},{\"type\":\"notes\",\"name\":\"rrt_code\",\"visitid\":\"ABCDEFG1234\",\"value\":\"\",\"date\":\"2021-07-04\",\"timestamp\":\"2021-07-04 00:00:00\",\"highlight\":{\"value_text_sentences\":[\"No signs of bleeding at this time. # New Afib with RVR and NSVT - already on AC with eliquis - on amiodarone per Dr. recommendations during RRT 07/4/21 early morning - ECHO ordered # elevated troponin due to NSVT and Afib+RVR as above - EKG reviewed - echo pending - patient already on AC and represent poor candidate for cardiac catheterization/antiplatelets given her pancypenia/<span class='highlighted'>thrombocytopenia</span> And metastatic cancer - will follow cards input #Acute hypoxemic resp failure due to lung cancer #Metastatic lung cancer to brain and liver per Hx Supportive care Received chemo x1 was to resume this month but LFTs elevated Follows at  palliative care on board #Acute liver injury / Abnormal LFT and jaundice probably due to chemo Trend LFT-->improving since 27563 admission Abdomen US: Fatty liver.No evidence of cholelithiasis within the limitations of examination.\"]},\"orderTimestamp\":1444320000000},{\"type\":\"notes\",\"name\":\"plan\",\"visitid\":\"ABCDEFG1234\",\"value\":\"\",\"date\":\"2021-07-05\",\"timestamp\":\"2021-07-05 00:00:00\",\"highlight\":{\"value_text_sentences\":[\"No signs of bleeding at this time. # New Afib with RVR and NSVT - already on AC with eliquis - on amiodarone per Dr. recommendations during RRT 07/4/21 early morning - ECHO ordered # elevated troponin due to NSVT and Afib+RVR as above - EKG reviewed - echo pending - patient already on AC and represent poor candidate for cardiac catheterization/antiplatelets given her pancypenia/<span class='highlighted'>thrombocytopenia</span> recent hematuria and patient is already on Eliquis.And metastatic cancer - HR much improved on Amiodarone now #Acute hypoxemic resp failure due to lung cancer #Metastatic lung cancer to brain and liver per Hx Supportive care Received chemo x1 was to resume this month but LFTs elevated Follows at  palliative care on board #Acute liver injury / Abnormal LFT and jaundice probably due to chemo Trend LFT-->improving since admission Abdomen US: Fatty liver.\"]},\"orderTimestamp\":1444406400000}]]}],\"chartTable\":[\"chart\",\"chart\",\"table\",\"table\",\"table\",\"table\",\"table\",\"table\",\"table\",\"table\",\"table\"],\"rupleNames\":[[\"Platelet count\"],[\" Platelet count\"],[\"SCDs noted\"],[\"SCDs noted\"],[\"Thrombocytopenia noted\"],[\"diagnosis_pancytopenia_present\"],[\"AC held\"],[\"AC held\"],[\"Bleeding noted\"],[\"GIB noted\"],[\"Thrombocytopenia noted\"]]}"
  ],
  "createdAt": "2021-12-14T16:40:19.334Z",
  "updatedAt": "2021-12-20T02:17:09.031Z"
}